,Drug_1,drug2,Level_of_interaction,Quality_of_interaction,Summary,Description
0,Idelalisib,Acarbose,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. After ingestion of acarbose, the majority of active unchanged drug remains in the lumen of the gastrointestinal tract to exert its pharmacological activity and is metabolised by intestinal enzymes and by the microbial flora. ",(See Summary)
1,Idelalisib,Acenocoumarol,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Acenocoumarol is mainly metabolised by CYP2C9 and to a lesser extent by CYP1A2 and CYP2C19. Idelalisib is an inducer of CYP2C9 and CYP2C19 in vitro but the in vivo effects have yet to be determined. As the clinical relevance of this interaction is unknown, monitoring may be required.",(See Summary)
2,Idelalisib,Acetylsalicylic acid (Aspirin),"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Aspirin is rapidly deacetylated to form salicylic acid and then further metabolised by glucuronidation (by several UGTs (major UGT1A6)). Idelalisib does not inhibit or induce UGT1A6. ,(See Summary)
3,Idelalisib,Agomelatine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Agomelatine is metabolised predominantly via CYP1A2 (90%), with a small proportion metabolised by CYP2C9 and CYP2C19 (10%). Idelalisib does not inhibit or induce CYP1A2.",(See Summary)
4,Idelalisib,Alendronic acid,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Alendronate is not metabolised and is cleared from the plasma by uptake into bone and elimination via renal excretion. Although no pharmacokinetic interaction is expected, alendronate should be separated from food or other medicinal products and patients must wait at least 30 minutes after taking alendronate before taking any other oral medicinal product.",(See Summary)
5,Idelalisib,Alfentanil,"
Do Not Coadminister
","
Low
","Coadministration has not been studied and should be avoided. Alfentanil undergoes extensive CYP3A4 metabolism. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of alfentanil. Therefore, coadministration should be avoided. If coadministration is clinically necessary, close monitoring for adverse reactions (e.g. respiratory depression, sedation) or dose titration is recommended. ",(See Summary)
6,Idelalisib,Alfuzosin,"
Do Not Coadminister
","
Low
","Coadministration has not been studied but should be avoided. Alfuzosin is metabolised by CYP3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of alfuzosin. Coadministration should be avoided. If possible, selection of an alternate concomitant medicinal product, with no or minimal metabolism via CYP3A4 should be considered.",(See Summary)
7,Idelalisib,Aliskiren,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Aliskiren is minimally metabolised and is mainly excreted unchanged in faeces. P-gp is a major determinant of aliskiren bioavailability. Idelalisib is an inhibitor of P-gp in vitro but a clinically relevant interaction with substrates of systemic P-gp are unlikely.,(See Summary)
8,Idelalisib,Allopurinol,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Allopurinol is converted to oxipurinol by xanthine oxidase and aldehyde oxidase. Idelalisib does not interfere with these metabolic pathways. ,(See Summary)
9,Idelalisib,Alosetron,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. In vitro data indicate that alosetron is metabolised by CYPs 2C9, 3A4 and 1A2. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may increase concentrations of alosetron. Although alosetron has a wide therapeutic index, the clinical relevance of this interaction is unknown and monitoring for toxicity may be required.",(See Summary)
10,Idelalisib,Alprazolam,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied and should be avoided. Alprazolam is mainly metabolised by CYP3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of alprazolam. Therefore, coadministration should be avoided. If coadministration is clinically necessary, close monitoring or dose titration is recommended.",(See Summary)
11,Idelalisib,Aluminium hydroxide,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Aluminium hydroxide is not metabolised by CYPs. Idelalisib is unlikely to interfere with this metabolic pathway. However, the solubility of idelalisib decreases with increasing pH of the stomach, but in patients with chronic lymphoid leukemia (CLL) and indolent non-Hodgkin lymphoma (iNHL), coadministration of idelalisib and acid-reducing agents did not demonstrate any clinically relevant effects. For patients with iNHL, idelalisib AUC and Cmax increased by 4% and 6%, respectively, whereas for patients with CLL, idelalisib AUC and Cmax decreased by 11% and 5%, respectively. Therefore, no clinically relevant interactions are expected. ",(See Summary)
12,Idelalisib,Ambrisentan,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but should be approached with caution. Ambrisentan is metabolised by glucuronidation via UGTs 1A3, 1A9 and 2B7, and to a lesser extent by CYP3A4 and CYP2C19. Ambrisentan is also a substrate of P-gp. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and idelalisib is an inhibitor of P-gp in vitro. Therefore, concentrations of ambrisentan may increase. The clinical relevance of this interaction is unknown; CYP3A4 mediated metabolism is a minor pathway and a clinically relevant interaction with substrates of systemic P-gp is unlikely. However, monitor closely for ambrisentan toxicity.",(See Summary)
13,Idelalisib,Amikacin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as amikacin is eliminated by glomerular filtration. Idelalisib does not interfere with this elimination pathway.,(See Summary)
14,Idelalisib,Amiloride,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amiloride is eliminated unchanged in the kidney. In vitro data indicate that amiloride is a substrate of OCT2. Idelalisib is unlikely to affect this elimination pathway.,(See Summary)
15,Idelalisib,Amiodarone,"
Do Not Coadminister
","
Low
","Coadministration has not been studied and should be avoided. Amiodarone is metabolised by CYP2C8 and CYP3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of amiodarone. Therefore, coadministration should be avoided. If possible, selection of an alternate concomitant medicinal product, with no or minimal metabolism via CYP3A4 should be considered.",(See Summary)
16,Idelalisib,Amisulpride,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amisulpride is weakly metabolised and is primarily renally eliminated (possibly via OCT). Idelalisib is unlikely to significantly affect these metabolic and elimination pathways. ,(See Summary)
17,Idelalisib,Amitriptyline,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amitriptyline is metabolised predominantly by CYP2D6 and CYP2C19 with a small proportion metabolised by CYPs 3A4, 1A2 and 2C9. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 but a clinically relevant interaction is unlikely.",(See Summary)
18,Idelalisib,Amlodipine,"
Do Not Coadminister
","
Low
","Coadministration has not been studied and should be avoided. Amlodipine is metabolised by CYP3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of amlodipine. Therefore, coadministration should be avoided. If coadministration is clinically necessary, close monitoring of therapeutic effect (blood pressure) and adverse reactions is recommended.",(See Summary)
19,Idelalisib,Amoxicillin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amoxicillin is mainly excreted in the urine by glomerular filtration and tubular secretion. In vitro data indicate that amoxicillin is a substrate of OAT3. Idelalisib is unlikely to interfere with this elimination pathway.,(See Summary)
20,Idelalisib,Amphotericin B,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Amphotericin B is not appreciably metabolised and is eliminated to a large extent in the bile. Idelalisib does not interfere with this elimination pathway. However, the European SPC for amphotericin B states that concomitant use of amphotericin B and antineoplastic agents can increase the risk of renal toxicity, bronchospasm and hypotension. Therefore, monitoring may be required. ",(See Summary)
21,Idelalisib,Ampicillin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Renal clearance of ampicillin occurs partly by glomerular filtration and partly by tubular secretion. About 20-40% of an oral dose may be excreted unchanged in the urine in 6 hours. After parenteral use about 60-80% is excreted in the urine within 6 hours. Idelalisib is unlikely to significantly inhibit ampicillin renal elimination.,(See Summary)
22,Idelalisib,Anidulafungin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Anidulafungin is not metabolised hepatically but undergoes chemical degradation at physiological temperatures. ,(See Summary)
23,Idelalisib,Antacids,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Antacids are not metabolised by CYPs and idelalisib is unlikely to affect the elimination of antacids. However, the solubility of idelalisib decreases with increasing pH of the stomach, but in patients with chronic lymphoid leukaemia (CLL) and indolent non-Hodgkin lymphoma (iNHL), coadministration of idelalisib and acid-reducing agents did not demonstrate any clinically relevant effects. For patients with iNHL, idelalisib AUC and Cmax increased by 4% and 6%, respectively, whereas for patients with CLL, idelalisib AUC and Cmax decreased by 11% and 5%, respectively. Therefore, no clinically relevant interactions are expected.",(See Summary)
24,Idelalisib,Apixaban,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied and should be avoided. Apixaban is metabolised by CYP3A4 and to a lesser extent by CYPs 1A2, 2C8, 2C9 and 2C19. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of apixaban. Therefore, coadministration should be avoided. If coadministration is clinically necessary, close monitoring of anti-Xa levels or dose titration is recommended. ",(See Summary)
25,Idelalisib,Aprepitant,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied but should be avoided. Aprepitant is mainly metabolised by CYP3A4 and to a lesser extent by CYP1A2 and CYP2C19. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase aprepitant exposure, thus prolonging and increasing aprepitant therapeutic activity and adverse reactions. Therefore, coadministration should be avoided. If coadministration is clinically necessary, monitor closely for aprepitant toxicity. Furthermore, during treatment aprepitant is a moderate inhibitor of CYP3A4 and may increase idelalisib concentrations. Since the therapeutic index of idelalisib is relatively large, it is not necessary to decrease the idelalisib dose a priori. However, close monitoring for toxicity is recommended. After treatment, aprepitant is a weak inducer of CYP3A4, CYP2C9 and UGT. Concentrations of idelalisib may decrease due to weak induction of CYP3A4, but this is not considered to be clinically relevant.",(See Summary)
26,Idelalisib,Aripiprazole,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied and should be avoided. Aripiprazole is metabolised by CYP3A4 and CYP2D6. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of aripiprazole. Therefore, coadministration should be avoided. If coadministration is clinically necessary, close monitoring or dose titration is recommended. ",(See Summary)
27,Idelalisib,Asenapine,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Asenapine is metabolised by glucuronidation (UGT1A4) and oxidative metabolism (via CYPs 1A2 (major), 3A4 and 2D6 (minor)). The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may increase concentrations of asenapine. Although CYP3A4 mediated metabolism is a minor pathway, the clinical relevance of this interaction is unknown and monitoring may be required. ",(See Summary)
28,Idelalisib,Astemizole,"
Potential Interaction
","
Very Low
","Coadministration has not been studied. Astemizole is metabolised by CYPs 2D6, 2J2 and 3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of astemizole. As the clinical relevance of this interaction is unknown, close monitoring may be required.",(See Summary)
29,Idelalisib,Atenolol,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Atenolol is mainly eliminated unchanged in the kidney, predominantly by glomerular filtration. Idelalisib does not interfere with this elimination pathway.",(See Summary)
30,Idelalisib,Atorvastatin,"
Do Not Coadminister
","
Low
","Coadministration has not been studied and should be avoided. Atorvastatin is metabolised by CYP3A4 and is a substrate of P-gp and OATP1B1. Idelalisib is an inhibitor of P-gp in vitro, but a clinically relevant interaction with substrates of systemic P-gp is unlikely. However, the primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of atorvastatin. Replacement of atorvastatin with pravastatin or rosuvastatin should be considered. If coadministration is unavoidable, clinical monitoring of atorvastatin toxicity and a lower starting dose of atorvastatin is recommended. ",(See Summary)
31,Idelalisib,Azathioprine,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Azathioprine is converted to 6-mercaptopurine which is metabolised analogously to natural purines. Idelalisib does not interfere with this metabolic pathway. However, due to the risk of additive haematological toxicity, haematological parameters should be monitored if coadministered.",(See Summary)
32,Idelalisib,Azithromycin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance and clinically significant interaction is unlikely. Azithromycin is mainly eliminated via biliary excretion with animal data suggesting this may occur via P-gp and MRP2. Idelalisib is an inhibitor of P-gp in vitro. However, a clinically relevant interaction is unlikely and no effect on idelalisib concentrations is expected. ",(See Summary)
33,Idelalisib,Beclometasone,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Beclometasone is a prodrug which is not metabolised by CYP450, but is hydrolysed via esterase enzymes to the highly active metabolite beclometasone -17-monopropionate. Idelalisib does not interact with this pathway. ",(See Summary)
34,Idelalisib,Bedaquiline,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied and should be avoided. Bedaquiline is metabolised by CYP3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of bedaquiline. Therefore, coadministration should be avoided. If coadministration is clinically necessary, close monitoring or dose titration is recommended. ",(See Summary)
35,Idelalisib,Bendroflumethiazide,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bendroflumethiazide is mainly eliminated by hepatic metabolism (70%) and excreted unchanged in the urine (30%) via OAT1 and OAT3. In vitro data indicate that bendroflumethiazide inhibits these renal transporters but a clinically relevant drug interaction is unlikely in the range of observed clinical concentrations. In addition, there is no evidence that bendroflumethiazide inhibits or induces CYP450 enzymes and therefore is unlikely to impact idelalisib.",(See Summary)
36,Idelalisib,Bepridil,"
Potential Interaction
","
Low
","Coadministration has not been studied and is not recommended. Bepridil is metabolised by CYP2D6 (major) and CYP3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of bepridil. Therefore, coadministration should be avoided. If coadministration is unavoidable, close clinical monitoring or dose titration is recommended.",(See Summary)
37,Idelalisib,Betamethasone,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied and should be avoided. Betamethasone is metabolised by CYP3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of betamethasone. Therefore, coadministration should be avoided. If coadministration is clinically necessary, close monitoring or dose titration is recommended. ",(See Summary)
38,Idelalisib,Bezafibrate,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Half of a bezafibrate dose is eliminated unchanged in the urine. In vitro data suggest that bezafibrate inhibits the renal transporter OAT1. Idelalisib is not transported by OAT1 and does not interfere with this elimination pathway.,(See Summary)
39,Idelalisib,Bisacodyl,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bisacodyl is converted to an active metabolite by intestinal and bacterial enzymes. Absorption from the gastrointestinal tract is minimal and the small amount absorbed is excreted in the urine as the glucuronide. Idelalisib does not interfere with this elimination pathway.,(See Summary)
40,Idelalisib,Bisoprolol,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied and should be avoided. Bisoprolol is partly metabolised by CYP3A4 and CYP2D6 and partly eliminated unchanged in the urine. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of bisoprolol. Therefore, coadministration should be avoided. If coadministration is clinically necessary, close monitoring of blood pressure or dose titration is recommended. ",(See Summary)
41,Idelalisib,Bosentan,"
Do Not Coadminister
","
Low
","Coadministration has not been studied and should be avoided. Bosentan is metabolised by CYP3A4 and CYP2C9. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and idelalisib is an inducer of CYP2C9 in vitro. Concentrations of bosentan may significantly increase due to inhibition of CYP3A4 but concentrations may decrease due to induction of CYP2C9. Coadministration should be approached with caution. If coadministration is clinically necessary, close monitoring for bosentan toxicity may be required. Furthermore, bosentan is also an inducer of CYP3A4 and may significantly decrease concentrations of idelalisib. Coadministration is not recommended as a decrease in idelalisib exposure can lead to decreased efficacy. Selection of an alternative concomitant medication with no or minimal enzyme or transporter induction potential is recommended. Increasing the dose of idelalisib when coadministering with moderate or strong CYP3A inducers has not been studied and thus no formal dose advice can be given ",(See Summary)
42,Idelalisib,Bromazepam,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bromazepam undergoes oxidative biotransformation. Interaction studies indicate that CYP3A4 plays a minor role in bromazepam metabolism, but other cytochromes such as CYP2D6 or CYP1A2 may also play a role. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4. Since CYP3A4 mediated metabolism is only a minor pathway, a clinically relevant interaction is unlikely.",(See Summary)
43,Idelalisib,Budesonide,"
Do Not Coadminister
","
Low
","Coadministration has not been studied and should be avoided. Budesonide is metabolised by CYP3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of budesonide. Therefore, coadministration should be avoided. If coadministration is clinically necessary, close monitoring for budesonide toxicity is recommended. ",(See Summary)
44,Idelalisib,Buprenorphine,"
Do Not Coadminister
","
Low
","Coadministration has not been studied and should be avoided. Buprenorphine undergoes both N-dealkylation to form norbuprenorphine (via CYP3A4) and glucuronidation (via UGT2B7 and UGT1A1). The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of buprenorphine. Therefore, coadministration should be avoided. If coadministration is clinically necessary, close monitoring for adverse reactions (e.g. respiratory depression, sedation) or dose titration is recommended.",(See Summary)
45,Idelalisib,Bupropion,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bupropion is primarily metabolised by CYP2B6. Idelalisib does not inhibit or induce CYP2B6.,(See Summary)
46,Idelalisib,Buspirone,"
Do Not Coadminister
","
Low
","Coadministration has not been studied and should be avoided. Buspirone is metabolised by CYP3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of buspirone. Therefore, coadministration should be avoided. If coadministration is clinically necessary, close monitoring for buspirone toxicity and a dose reduction of buspirone should be considered.",(See Summary)
47,Idelalisib,Calcium,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Calcium is eliminated through faeces, urine and sweat. ",(See Summary)
48,Idelalisib,Candesartan,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Candesartan is mainly eliminated unchanged via urine and bile. ,(See Summary)
49,Idelalisib,Capreomycin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Capreomycin is predominantly excreted via the kidneys as unchanged drug. Idelalisib does not interfere with this elimination pathway. ,(See Summary)
50,Idelalisib,Captopril,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Captopril is largely excreted in the urine by OAT1. Idelalisib does not interfere with this elimination pathway.,(See Summary)
51,Idelalisib,Carbamazepine,"
Do Not Coadminister
","
Low
","Coadministration has not been studied but should be avoided. Carbamazepine is primarily metabolised by CYP3A4 and to a lesser extent by CYP2C8. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of carbamazepine. Therefore, coadministration should be avoided. If coadministration is clinically necessary, close monitoring of carbamazepine plasma concentrations is recommended. Idelalisib is also an inhibitor of CYP2C8 in vitro. The clinical relevance of this interaction is unknown. However, no clinically significant interaction is expected, since CYP2C8 is a minor pathway. Furthermore, carbamazepine is an inducer of CYPs 2C8 (strong), 2C9 (strong), 3A4 (strong), 1A2 (weak), 2B6 and UGT1A1. Carbamazepine may significantly decrease concentrations of idelalisib due to induction of CYP3A4. Coadministration should be avoided as a decrease in idelalisib exposure can lead to decreased efficacy. Selection of an alternative concomitant medication with no or minimal enzyme or transporter induction potential is recommended. Increasing the dose of idelalisib when coadministering with moderate or strong CYP3A inducers has not been studied and thus no formal dose advice can be given.",(See Summary)
52,Idelalisib,Carvedilol,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Carvedilol undergoes glucuronidation via UGTs 1A1, 2B4 and 2B7, and metabolism via CYP2D6 and to a lesser extent CYPs 2C9 and 1A2. Idelalisib does not inhibit or induce these CYPs or UGTs.  ",(See Summary)
53,Idelalisib,Caspofungin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Caspofungin undergoes spontaneous chemical degradation and metabolism via a non CYP-mediated pathway. Idelalisib does not interact with this metabolic pathway. ,(See Summary)
54,Idelalisib,Cefalexin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cefalexin is predominantly renally eliminated unchanged by glomerular filtration and tubular secretion via OAT1 and MATE1. Idelalisib does not interfere with this elimination pathway.,(See Summary)
55,Idelalisib,Cefazolin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cefazolin is predominantly excreted unchanged in the urine, mainly by glomerular filtration with some renal tubular secretion via OAT3. Idelalisib does not interfere with this elimination pathway.",(See Summary)
56,Idelalisib,Cefixime,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cefixime is renally excreted predominantly by glomerular filtration. Idelalisib does not interfere with this elimination pathway.,(See Summary)
57,Idelalisib,Cefotaxime,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cefotaxime is partially metabolised by non-specific esterases. Most of a dose of cefotaxime is excreted in the urine - about 60% as unchanged drug and a further 24% as desacetyl-cefotaxime, an active metabolite. In vitro studies indicate that OAT3 participates in the renal elimination of cefotaxime. Idelalisib does not interfere with this elimination pathway.",(See Summary)
58,Idelalisib,Ceftazidime,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as ceftazidime is excreted predominantly by renal glomerular filtration. Idelalisib does not interfere with this elimination pathway.,(See Summary)
59,Idelalisib,Ceftriaxone,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ceftriaxone is eliminated mainly as unchanged drug, approximately 60% of the dose being excreted in the urine predominantly by glomerular filtration and the remainder via the biliary and intestinal tracts. Idelalisib does not interfere with this elimination pathway.",(See Summary)
60,Idelalisib,Celecoxib,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Celecoxib is primarily metabolised by CYP2C9. Idelalisib does not inhibit or induce CYP2C9. ,(See Summary)
61,Idelalisib,Cetirizine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cetirizine is only metabolised to a limited extent and is eliminated unchanged in the urine through both glomerular filtration and tubular secretion. In vitro data indicate that cetirizine inhibits OCT2. Idelalisib is not transported by OCT2 and is unlikely to interfere with this elimination pathway.,(See Summary)
62,Idelalisib,Chloramphenicol,"
Potential Interaction
","
Very Low
","Coadministration has not been studied. Chloramphenicol is predominately glucuronidated. Idelalisib does not inhibit or induce UGTs. However, in vitro studies have shown that chloramphenicol inhibits CYP3A4 and may increase concentrations of idelalisib. Since the therapeutic index of idelalisib is relatively large, no a priori dose adjustment is necessary but close monitoring for toxicity is recommended. Ocular use: Although chloramphenicol is systemically absorbed when used topically in the eye, the concentrations used are unlikely to cause a clinically significant interaction. ",(See Summary)
63,Idelalisib,Chlordiazepoxide,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied but should be avoided. Chlordiazepoxide is extensively metabolised by CYP3A4, but does not inhibit or induce cytochromes. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase chlordiazepoxide systemic exposure and thereby activity and toxicity. If coadministration is unavoidable, a dose reduction may be required and close monitoring is recommended. ",(See Summary)
64,Idelalisib,Chlorphenamine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Chlorphenamine is predominantly metabolised in the liver via CYP2D6. Idelalisib does not inhibit or induce CYP2D6.  ,(See Summary)
65,Idelalisib,Chlorpromazine,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Chlorpromazine is metabolised mainly by CYP2D6, but also by CYP1A2 and CYP3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may increase concentrations of chlorpromazine. Although CYP3A4 mediated metabolism is a minor pathway, the clinical relevance of this interaction is unknown and monitoring may be required. ",(See Summary)
66,Idelalisib,Chlortalidone,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Chlortalidone is mainly excreted unchanged in the urine and faeces. ,(See Summary)
67,Idelalisib,Ciclosporin (Cyclosporine),"
Do Not Coadminister
","
Low
","Coadministration has not been studied and should be avoided. Ciclosporin is an inhibitor of CYP3A4 and may increase concentrations of idelalisib. Since the therapeutic index of idelalisib is relatively large, no a priori dose adjustment is necessary but close monitoring for toxicity is recommended. Furthermore, ciclosporin is metabolised by CYP3A4 and is a substrate of P-gp. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of ciclosporin. Therefore, coadministration should be avoided. If coadministration is clinically necessary, the dose of ciclosporin should be decreased dependent on the indication and protocol involved, and monitoring of ciclosporin plasma concentrations is recommended. Due to the risk of additive haematological toxicity, haematological parameters should also be monitored if coadministered.",(See Summary)
68,Idelalisib,Cilazapril,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cilazapril is mainly eliminated unchanged in the kidneys. ,(See Summary)
69,Idelalisib,Cimetidine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cimetidine is an inhibitor of CYP3A4 and in vitro data indicate that cimetidine inhibits OAT1 and OCT2 but at concentrations much higher than the observed clinical concentrations. Concentrations of idelalisib may increase due to inhibition of CYP3A4 but a clinically relevant interaction is unlikely. Furthermore, the solubility of idelalisib decreases with increasing pH of the stomach, but in patients with chronic lymphoid leukaemia (CLL) and indolent non-Hodgkin lymphoma (iNHL), coadministration of idelalisib and acid-reducing agents did not demonstrate any clinically relevant effects. For patients with iNHL, idelalisib AUC and Cmax increased by 4% and 6%, respectively, whereas for patients with CLL, idelalisib AUC and Cmax decreased by 11% and 5%, respectively. Therefore, no clinically relevant interactions are expected.",(See Summary)
70,Idelalisib,Ciprofloxacin,"
Potential Interaction
","
Very Low
","Coadministration has not been studied. Ciprofloxacin is primarily eliminated unchanged in the kidneys by glomerular filtration and tubular secretion via OAT3. Ciprofloxacin is also metabolised and partially cleared through the bile and intestine. Idelalisib does not interfere with the elimination of ciprofloxacin. However, ciprofloxacin is a weak to moderate inhibitor of CYP3A4 and a strong inhibitor of CYP1A2. Concentrations of idelalisib may increase due to inhibition of CYP3A4. Since the therapeutic index of idelalisib is relatively large, no a priori dose adjustment is necessary, but close monitoring for toxicity is recommended.",(See Summary)
71,Idelalisib,Cisapride,"
Do Not Coadminister
","
Low
","Coadministration has not been studied and should be avoided. Cisapride is metabolised by CYP3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of cisapride. Therefore, coadministration should be avoided. If possible, selection of an alternate concomitant medicinal product, with no or minimal metabolism via CYP3A4 should be considered.",(See Summary)
72,Idelalisib,Citalopram,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Citalopram is metabolised by CYPs 2C19 (38%), 2D6 (31%) and 3A4 (31%). The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and idelalisib is an inducer of CYP2C19 in vitro. Concentrations of citalopram may increase due to inhibition of CYP3A4. As multiple metabolic pathways play a role, no a priori dose adjustment of citalopram is necessary. As the clinical relevance of this interaction is unknown, monitoring for toxicity may be required.",(See Summary)
73,Idelalisib,Clarithromycin,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied and should be avoided. Clarithromycin is an inhibitor of CYP3A4 and may increase concentrations of idelalisib. Since the therapeutic index of idelalisib is relatively large, no a priori dose adjustment is necessary but close monitoring for toxicity is recommended. However, clarithromycin is metabolised by CYP3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of clarithromycin. Therefore, coadministration should be avoided. If coadministration is clinically necessary, close monitoring for clarithromycin associated adverse events is recommended. No a priori dose adjustment of clarithromycin is needed for patients with normal renal function or mild renal impairment (creatinine clearance (CrCl 60-90 mL/min). In patients with moderate to severe renal impairment (CrCl <60 mL/min) an alternative antibacterial should be considered. ",(See Summary)
74,Idelalisib,Clavulanic acid,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clavulanic acid is extensively metabolised (likely non-CYP mediated pathway) and excreted in the urine by glomerular filtration. Idelalisib does not interact with these metabolic and elimination pathways. ,(See Summary)
75,Idelalisib,Clemastine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clemastine is predominantly metabolised in the liver via CYP2D6. Idelalisib does not inhibit or induce CYP2D6.  ,(See Summary)
76,Idelalisib,Clindamycin,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied and should be avoided. Clindamycin is metabolised by CYP3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of clindamycin. Therefore, coadministration should be avoided. If coadministration is clinically necessary, close monitoring or dose titration is recommended. ",(See Summary)
77,Idelalisib,Clobetasol,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely with the topical use of clobetasol.,(See Summary)
78,Idelalisib,Clofazimine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clofazimine is largely excreted unchanged in the faeces, both as unabsorbed drug and via biliary excretion. Idelalisib does not interfere with this elimination pathway. ",(See Summary)
79,Idelalisib,Clofibrate,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clofibrate is hydrolysed to an active metabolite, clofibric acid. Excretion of clofibric acid glucuronide is possibly performed via OAT1. Idelalisib does not interfere with this elimination pathway.",(See Summary)
80,Idelalisib,Clomipramine,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Clomipramine is metabolised by CYPs 3A4, 1A2 and 2C19 to desmethylclomipramine, an active metabolite which has a higher activity than the parent drug. In addition, clomipramine and desmethylclomipramine are metabolised by CYP2D6. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and idelalisib is an inducer of CYP2C19 in vitro. Concentrations of clomipramine may increase due to inhibition of CYP3A4 but concentrations may decrease due to induction of CYP2C9 and CYP2C19. Concentrations of the active metabolite may also be altered. As multiple metabolic pathways play a role, no a priori dose adjustment of clomipramine is necessary. As the clinical relevance of this interaction is unknown, monitoring may be required.",(See Summary)
81,Idelalisib,Clonidine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Approximately 70% of administered clonidine is excreted in the urine, mainly in the form of the unchanged parent drug (40-60% of the dose). Clonidine is a weak inhibitor of OCT2 but is unlikely to interact with idelalisib elimination. In addition, idelalisib does not interfere with clonidine elimination.",(See Summary)
82,Idelalisib,Clopidogrel,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied and should be avoided. Clopidogrel is a prodrug and is converted to its active metabolite via CYPs 3A4, 2B6, 2C19 and 1A2. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of clopidogrel and thus decrease concentrations of the active metabolite. Coadministration should be avoided and selection of an alternate concomitant medicinal product, with no or minimal potential to interact with bioactivation of clopidogrel should be considered.",(See Summary)
83,Idelalisib,Clorazepate,"
Do Not Coadminister
","
Low
","Coadministration has not been studied and should be avoided. Clorazepate is rapidly converted to nordiazepam which is then metabolised to oxazepam by CYP3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of clorazepate. Therefore, coadministration should be avoided. If coadministration is clinically necessary, close monitoring for clorazepate toxicity and a dose reduction of clorazepate should be considered.",(See Summary)
84,Idelalisib,Cloxacillin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cloxacillin is metabolised to a limited extent, and the unchanged drug and metabolites are excreted in the urine by glomerular filtration and renal tubular secretion. Idelalisib does not interact with this elimination pathway.",(See Summary)
85,Idelalisib,Clozapine,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied but should be avoided. Clozapine is metabolised mainly by CYP1A2 and CYP3A4, and to a lesser extent by CYP2C19 and CYP2D6. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may cause a significant increase of clozapine systemic exposure and thereby activity and toxicity. Coadministration should be avoided. If coadministration is clinically necessary, the dose of clozapine might need to be reduced and close monitoring is recommended. Furthermore, due to the risk of additive haematological toxicity, haematological parameters should be monitored if coadministered.",(See Summary)
86,Idelalisib,Codeine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Codeine is converted via CYP2D6 to morphine, an active metabolite with analgesic and opioid properties. Morphine is further metabolised by conjugation with glucuronic acid to morphine-3-glucuronide (inactive) and morphine-6-glucuronide (active). Morphine is also a substrate of P-gp. Idelalisib is an inhibitor of P-gp in vitro, but this is unlikely to be clinically relevant. Furthermore, codeine is converted via CYP3A4 to norcodeine, an inactive metabolite. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4, but since CYP3A4 mediated metabolism is a minor pathway, a clinically relevant interaction is unlikely.",(See Summary)
87,Idelalisib,Colchicine,"
Do Not Coadminister
","
Low
","Coadministration has not been studied and should be avoided. Colchicine is metabolised by CYP3A4 and is a substrate of P-gp. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of colchicine. Therefore, coadministration should be avoided, especially with patients with renal or hepatic impairment. If coadministration is clinically necessary, close monitoring for colchicine toxicity and a dose reduction of colchicine may be required. ",(See Summary)
88,Idelalisib,Cycloserine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cycloserine is predominantly renally excreted via glomerular filtration. Idelalisib does not interact with this elimination pathway.,(See Summary)
89,Idelalisib,Dabigatran,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Dabigatran is transported via P-gp and is renally excreted. Idelalisib is an inhibitor of P-gp in vitro. Although the in vivo effect has yet to be determined, increased exposure of sensitive substrates of intestinal P-gp, such as dabigatran cannot be excluded and monitoring may be required.",(See Summary)
90,Idelalisib,Dalteparin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dalteparin is excreted largely unchanged via the kidneys. Idelalisib does not interfere with the renal excretion of dalteparin. ,(See Summary)
91,Idelalisib,Dapsone,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Metabolism of dapsone is mainly by N-acetylation with a component of N-hydroxylation, and is via multiple CYP450 enzymes. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may increase concentrations of dapsone. As the clinical relevance of this interaction is unknown, monitoring may be required.",(See Summary)
92,Idelalisib,Desipramine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as desipramine is metabolised by CYP2D6. Idelalisib does not inhibit or induce CYP2D6.,(See Summary)
93,Idelalisib,Desogestrel,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Desogestrel is a prodrug which is activated to etonogestrel by CYP2C9 (and possibly CYP2C19); the metabolism of etonogestrel is mediated by CYP3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and idelalisib is an inducer of CYP2C9 and CYP2C19 in vitro. Concentrations of etonogestrel may increase due to inhibition of CYP3A4 and induction of CYP2C9 and CYP2C19 by idelalisib. Although desogestrel has a wide therapeutic window, the clinical relevance of this interaction is unknown and monitoring may be required. The SPC for idelalisib states that women using hormonal contraceptives should add a barrier method as a second form of contraception while taking idelalisib and for 1 month after stopping treatment, as it is currently unknown whether idelalisib may reduce the effectiveness.",(See Summary)
94,Idelalisib,Dexamethasone,"
Potential Interaction
","
Very Low
","Coadministration has not been studied and should be avoided. Dexamethasone is metabolised by CYP3A4 and is a substrate of P-gp. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of dexamethasone. Therefore, coadministration should be avoided. If coadministration is clinically necessary, close monitoring for dexamethasone toxicity is recommended. Dexamethasone has been described as a weak inducer of CYP3A4 and could possibly decrease idelalisib plasma concentrations. Coadministration should be avoided as a decrease in exposure can lead to decreased efficacy. Selection of an alternative concomitant medication with no or minimal enzyme or transporter induction potential is recommended. ",(See Summary)
95,Idelalisib,Dextropropoxyphene,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied and should be avoided. Dextropropoxyphene is mainly metabolised by CYP3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of dextropropoxyphene. Therefore, coadministration should be avoided. If coadministration is clinically necessary, close monitoring for adverse reactions (e.g. respiratory depression, sedation) or dose titration is recommended.",(See Summary)
96,Idelalisib,Diamorphine (diacetylmorphine),"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Diamorphine is rapidly metabolised by sequential deacetylation to morphine which is then mainly glucuronidated to morphine-3-glucuronide (UGT2B7>UGT1A1) and to a lesser extent, to the pharmacologically active morphine-6-glucuronide (UGT2B7>UGT1A1). Idelalisib does not inhibit or induce UGTs. ",(See Summary)
97,Idelalisib,Diazepam,"
Do Not Coadminister
","
Low
","Coadministration has not been studied and should be avoided. Diazepam is metabolised to nordiazepam (via CYP3A4 and CYP2C19) and to temazepam (mainly by CYP3A4). The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of diazepam. In an individual case report involving one individual, coadministration of idelalisib (150 mg twice daily) and diazepam (5 mg twice daily) resulted in hospitalisation due to altered mental status and type II respiratory failure. Therefore, coadministration should be avoided. If coadministration is clinically necessary, close monitoring for diazepam toxicity and a dose reduction of diazepam should be considered.",(See Summary)
98,Idelalisib,Diclofenac,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Diclofenac is partly glucuronidated by UGT2B7 and partly oxidised by CYP2C9. Idelalisib does not inhibit or induce these CYPs or UGTs. ,(See Summary)
99,Idelalisib,Digoxin,"
No Interaction Expected
","
Moderate
","Digoxin is renally eliminated via the renal transporters OATP4C1 and P-gp. Idelalisib is an inhibitor of P-gp in vitro but a clinically relevant interaction is unlikely with substrates of systemic P-gp. In healthy volunteers (n=12), coadministration of idelalisib (150 mg twice daily for 10 days) and digoxin (single dose of 0.5 mg) increase digoxin Cmax by 24%. The AUC remained unchanged. As expected, idelalisib pharmacokinetics were not impacted by digoxin.",(See Summary)
100,Idelalisib,Dihydrocodeine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dihydrocodeine undergoes predominantly direct glucuronidation, with CYP3A4 mediated metabolism accounting for only 5-10% of the overall metabolism. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 but since CYP3A4 mediated metabolism is only a minor pathway, a clinically relevant interaction is unlikely.",(See Summary)
101,Idelalisib,Diltiazem,"
Do Not Coadminister
","
Low
","Coadministration has not been studied and should be avoided. Diltiazem is a moderate inhibitor of CYP3A4 and may increase concentrations of idelalisib. Since the therapeutic index of idelalisib is relatively large, no a priori dose adjustment is necessary but close monitoring for toxicity is recommended. Furthermore, diltiazem is metabolised by CYP3A4 and CYP2D6. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of diltiazem. Therefore, coadministration should be avoided. If coadministration is clinically necessary, close monitoring of therapeutic effect (blood pressure) and adverse reactions is recommended.",(See Summary)
102,Idelalisib,Diphenhydramine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Diphenhydramine is mainly metabolised by CYP2D6 and to a lesser extent by CYPs 1A2, 2C9 and 2C19. Idelalisib does not inhibit or induce these CYPs. ",(See Summary)
103,Idelalisib,Dipyridamole,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dipyridamole is glucuronidated by many UGTs, specifically those of the UGT1A subfamily. Idelalisib does not inhibit or induce UGTs.",(See Summary)
104,Idelalisib,Disopyramide,"
Potential Interaction
","
Low
","Coadministration has not been studied and is not recommended. Disopyramide is metabolised by CYP3A4 (25%) and 50% of the drug is eliminated unchanged in the urine. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of disopyramide. Therefore, coadministration should be avoided. If coadministration is unavoidable, close clinical monitoring or dose titration is recommended.",(See Summary)
105,Idelalisib,Dolasetron,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dolasetron is converted by carbonyl reductase to its active metabolite, hydrodolasetron, which is mainly glucuronidated (60%) and metabolised by CYP2D6 (10-20%) and CYP3A4 (<1%). The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4. However, since CYP3A4-mediated metabolism is only a minor pathway, a clinically relevant interaction is unlikely. ",(See Summary)
106,Idelalisib,Domperidone,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied and should be avoided. Domperidone is mainly metabolised by CYP3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of domperidone. Therefore, coadministration should be avoided. If coadministration is clinically necessary, close monitoring or dose titration is recommended. ",(See Summary)
107,Idelalisib,Dopamine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dopamine is metabolised in the liver, kidneys, and plasma by monoamine oxidase (MAO), and catechol-O-methyltransferase to inactive compounds. About 25% of a dose of dopamine is metabolised to norepinephrine within the adrenergic nerve terminals. There is little potential for dopamine to affect disposition of idelalisib, or to be affected if co-administered with idelalisib.",(See Summary)
108,Idelalisib,Doxazosin,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied and should be avoided. Doxazosin is metabolised mainly by CYP3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of doxazosin. Therefore, coadministration should be avoided. If coadministration is clinically necessary, close monitoring or dose titration is recommended. ",(See Summary)
109,Idelalisib,Doxepin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Doxepin is metabolised to nordoxepin (a metabolite with comparable pharmacological activity as the parent compound) mainly by CYP2C19. In addition, doxepin and nordoxepin are metabolised by CYP2D6. Idelalisib does not inhibit or induce CYP2D6 and CYP2C19. ",(See Summary)
110,Idelalisib,Doxycycline,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Doxycycline is excreted in the urine and faeces as unchanged active substance. Between 40-60% of an administered dose can be accounted for in the urine. Idelalisib does not interact with this pathway. ,(See Summary)
111,Idelalisib,Dronabinol,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Dronabinol is mainly metabolised by CYP2C9 and to a lesser extent by CYP3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and idelalisib is an inducer of CYP2C9 in vitro. Concentrations of dronabinol may increase due to inhibition of CYP3A4 but concentrations may decrease due to induction of CYP2C9. As the clinical relevance of this interaction is unknown, monitoring for toxicity may be required.",(See Summary)
112,Idelalisib,Drospirenone,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Drospirenone is metabolised to a minor extent via CYP3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may increase concentrations of drospirenone. Although CYP3A4 mediated metabolism is only a minor pathway, the clinical relevance of this is interaction is unknown and monitoring for toxicity may be required. The SPC for idelalisib states that women using hormonal contraceptives should add a barrier method as a second form of contraception while taking idelalisib and for 1 month after stopping treatment, as it is currently unknown whether idelalisib may reduce the effectiveness.",(See Summary)
113,Idelalisib,Dulaglutide,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dulaglutide is degraded by endogenous endopeptidases. Dulaglutide delays gastric emptying and could possibly decrease the absorption rate of concomitantly administered oral drugs. Since idelalisib efficacy is more likely to be correlated to trough plasma concentrations instead of maximum plasma concentrations, the clinical relevance of delayed absorption is considered to be limited.",(See Summary)
114,Idelalisib,Duloxetine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Duloxetine is metabolised by CYP2D6 and CYP1A2. Idelalisib does not inhibit or induce CYP2D6 and CYP1A2.,(See Summary)
115,Idelalisib,Dutasteride,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied and should be avoided. Dutasteride is mainly metabolised by CYP3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of dutasteride. Therefore, coadministration should be avoided. If coadministration is clinically necessary, close monitoring or dose titration is recommended. ",(See Summary)
116,Idelalisib,Dydrogesterone,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Dydrogesterone is metabolised to dihydrodydrogesterone (possibly via CYP3A4). The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may increase concentrations of dydrogesterone. Although CYP3A4 mediated metabolism is only a minor pathway, the clinical relevance of this is interaction is unknown and monitoring for toxicity may be required. ",(See Summary)
117,Idelalisib,Edoxaban,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Edoxaban is partially metabolised by CYP3A4 (<10%) and is transported via P-gp. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and idelalisib is an inhibitor of P-gp in vitro. Since CYP3A4 mediated metabolism is only a minor pathway and systemic P-gp is involved, a clinically relevant interaction is unlikely. ",(See Summary)
118,Idelalisib,Eltrombopag,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Eltrombopag is metabolised by cleavage conjugation (via UGT1A1 and UGT1A3) and oxidation (via CYP1A2 and CYP2C8). Idelalisib is an inhibitor of CYP2C8 in vitro. As the clinically relevance of this interaction is unknown, monitoring may be required. ",(See Summary)
119,Idelalisib,Enalapril,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Enalapril is hydrolysed to enalaprilat which is renally eliminated (possibly via OATs). Idelalisib does not interact with this elimination pathway.,(See Summary)
120,Idelalisib,Enoxaparin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Enoxaparin does not undergo cytochrome metabolism; it is desulphated and depolymerised in the liver, and then predominately renally excreted. Idelalisib does not interact with these metabolic or elimination pathways.",(See Summary)
121,Idelalisib,Eprosartan,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as eprosartan is largely excreted in bile and urine as unchanged drug. ,(See Summary)
122,Idelalisib,Ertapenem,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ertapenem is mainly eliminated in the kidneys by glomerular filtration with tubular secretion playing a minor role. Idelalisib does not interact with this elimination pathway.,(See Summary)
123,Idelalisib,Erythromycin,"
Potential Interaction
","
Very Low
","Coadministration has not been studied. Erythromycin is an inhibitor of CYP3A4 and may increase concentrations of idelalisib. Since the therapeutic index of idelalisib is relatively large, no a priori dose adjustment is necessary but close monitoring for toxicity is recommended. Furthermore, erythromycin is metabolised by CYP3A4. The primary metabolite of idelalisib (GS-563117) is a strong inducer of CYP3A4 and may significantly increase erythromycin concentrations. Therefore, coadministration should be avoided. If coadministration of is clinically necessary, close monitoring or dose titration is recommended. ",(See Summary)
124,Idelalisib,Escitalopram,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Escitalopram is metabolised by CYPs 2C19 (37%), 2D6 (28%) and 3A4 (35%) to form N-desmethylescitalopram. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may increase concentrations of escitalopram. As multiple metabolic pathways play a role, no a priori dose adjustment of citalopram is necessary. As the clinical relevance of this interaction is unknown, monitoring for toxicity may be required.",(See Summary)
125,Idelalisib,Esomeprazole,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Esomeprazole is metabolised by CYP2C19 and CYP3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and idelalisib is an inducer of CYP2C19 in vitro. Concentrations of esomeprazole may increase due to inhibition of CYP3A4 but concentrations may decrease due to induction of CYP2C19. Although esomeprazole has a wide therapeutic index, the clinical relevance of this interaction is unknown and monitoring for toxicity may be required. The solubility of idelalisib decreases with increasing pH of the stomach. However, in patients with chronic lymphoid leukaemia (CLL) and indolent non-Hodgkin lymphoma (iNHL), coadministration of idelalisib and acid-reducing agents did not demonstrate any clinically relevant effects. For patients with iNHL, idelalisib AUC and Cmax increased by 4% and 6%, respectively, whereas for patients with CLL, idelalisib AUC and Cmax decreased by 11% and 5%, respectively. Therefore, no clinically relevant interactions are expected.",(See Summary)
126,Idelalisib,Estazolam,"
Do Not Coadminister
","
Low
","Coadministration has not been studied and should be avoided. Estazolam is metabolised to its major metabolite, 4-hydroxyestazolam, via CYP3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of estazolam. Therefore, coadministration should be avoided. If coadministration is clinically necessary, close monitoring for estazolam toxicity and a dose reduction of estazolam should be considered.",(See Summary)
127,Idelalisib,Estradiol,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Estradiol is metabolised by CYP3A4, CYP1A2 and is glucuronidated. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and idelalisib is an inducer of UGT in vitro. Concentrations of estradiol may increase due to inhibition of CYP3A4 by idelalisib but concentrations may decrease due to induction of UGT. Although CYP3A4 mediated metabolism is one of multiple pathways, the clinical relevance of this is interaction is unknown and monitoring for toxicity may be required. The SPC for idelalisib states that women using hormonal contraceptives should add a barrier method as a second form of contraception while taking idelalisib and for 1 month after stopping treatment, as it is currently unknown whether idelalisib may reduce the effectiveness.",(See Summary)
128,Idelalisib,Ethambutol,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ethambutol is partly metabolised by alcohol dehydrogenase (20%) and partly eliminated unchanged in the faeces (20%) and urine (50%). Idelalisib does not interact with this metabolic or elimination pathway.,(See Summary)
129,Idelalisib,Ethinylestradiol,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Ethinylestradiol undergoes oxidation (CYP3A4>CYP2C9), sulfation and glucuronidation (UGT1A1). The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and idelalisib is an inducer of UGT in vitro. Concentrations of ethinylestradiol may increase due to inhibition of CYP3A4 but concentrations may decrease due to induction of UGT. Although CYP3A4 mediated metabolism is only a minor pathway, the clinical relevance of this is interaction is unknown and monitoring for toxicity may be required. The SPC for idelalisib states that women using hormonal contraceptives should add a barrier method as a second form of contraception while taking idelalisib and for 1 month after stopping treatment, as it is currently unknown whether idelalisib may reduce the effectiveness.",(See Summary)
130,Idelalisib,Ethionamide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ethionamide is extensively metabolised in the liver with animal studies suggesting involvement of flavin-containing monooxygenases. Idelalisib does not interfere with this metabolic pathway. ,(See Summary)
131,Idelalisib,Etonogestrel,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Etonogestrel is metabolised by CYP3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may increase concentrations of etonogestrel. Although etonogestrel has a wide therapeutic window, the clinical relevance of this interaction is unknown and monitoring may be required. The SPC for idelalisib states that women using hormonal contraceptives should add a barrier method as a second form of contraception while taking idelalisib and for 1 month after stopping treatment, as it is currently unknown whether idelalisib may reduce the effectiveness.",(See Summary)
132,Idelalisib,Everolimus (Immunosuppressant),"
Do Not Coadminister
","
Very Low
","Coadministration has been studied but should be avoided. Everolimus is metabolised via CYP3A4 and is a substrate of P-gp. Although idelalisib is an inhibitor of P-gp in vitro, this is unlikely to be clinically relevant. However, the primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase the systemic exposure of everolimus, leading to increased or prolonged everolimus therapeutic activity and adverse reactions. Coadministration should be avoided. If coadministration is clinically necessary, close monitoring of everolimus tolerance is recommended. ",(See Summary)
133,Idelalisib,Exenatide,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as exenatide is cleared mainly by glomerular filtration. Exenatide delays gastric emptying and could possibly decrease the absorption rate of concomitantly administered oral drugs. Since idelalisib efficacy is more likely to be correlated to trough plasma concentrations instead of maximum plasma concentrations, the clinical relevance of delayed absorption is considered to be limited.",(See Summary)
134,Idelalisib,Ezetimibe,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ezetimibe is glucuronidated by UGTs 1A1 and 1A3 and to a lesser extent by UGTs 2B15 and 2B7. Idelalisib does not inhibit or induce these UGTs. ,(See Summary)
135,Idelalisib,Famotidine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Famotidine is excreted via OAT1/OAT3. Idelalisib does not interact with this elimination pathway. However, the solubility of idelalisib decreases with increasing pH of the stomach, but in patients with chronic lymphoid leukaemia (CLL) and indolent non-Hodgkin lymphoma (iNHL), coadministration of idelalisib and acid-reducing agents did not demonstrate any clinically relevant effects. For patients with iNHL, idelalisib AUC and Cmax increased by 4% and 6%, respectively, whereas for patients with CLL, idelalisib AUC and Cmax decreased by 11% and 5%, respectively. Therefore, no clinically relevant interactions are expected.",(See Summary)
136,Idelalisib,Felodipine,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied and should be avoided. Felodipine is metabolised by CYP3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of felodipine. Therefore, coadministration should be avoided. If coadministration is clinically necessary, close monitoring of therapeutic effect (blood pressure) and adverse reactions is recommended.",(See Summary)
137,Idelalisib,Fenofibrate,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fenofibrate is hydrolysed to an active metabolite, fenofibric acid. In vitro data suggest that fenofibric acid inhibits OAT3. Idelalisib is not transported by OAT3 and does not interact with this metabolic pathway.",(See Summary)
138,Idelalisib,Fentanyl,"
Do Not Coadminister
","
Low
","Coadministration has not been studied and should be avoided. Fentanyl undergoes extensive CYP3A4 metabolism. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of fentanyl. Therefore, coadministration should be avoided. If coadministration is clinically necessary, close monitoring for adverse reactions (e.g. respiratory depression, sedation) or dose titration is recommended.",(See Summary)
139,Idelalisib,Fexofenadine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fexofenadine undergoes negligible metabolism and is mainly eliminated unchanged in the faeces. Idelalisib does not interfere with this elimination pathway.,(See Summary)
140,Idelalisib,Finasteride,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied and should be avoided. Finasteride is metabolised by CYP3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of finasteride. Therefore, coadministration should be avoided. If coadministration is clinically necessary, close monitoring or dose titration is recommended.",(See Summary)
141,Idelalisib,Fish oils,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. ,(See Summary)
142,Idelalisib,Flecainide,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Flecainide is metabolised mainly via CYP2D6, with a proportion (approximately 30%) of the parent drug also renally eliminated unchanged. Idelalisib does not interact with these metabolic or elimination pathways. ",(See Summary)
143,Idelalisib,Flucloxacillin,"
Potential Interaction
","
Very Low
","Coadministration has not been studied. Flucloxacillin is mainly renally eliminated partly by glomerular filtration and partly by active secretion via OAT1. Idelalisib does not interact with these pathways. However, flucloxacillin was shown to induce CYP3A4 and P-gp and may decrease concentrations of idelalisib. Therefore, coadministration should be avoided as a decrease in idelalisib exposure can lead to decreased efficacy. Selection of an alternative concomitant medication with no or minimal enzyme or transporter induction potential is recommended. Increasing the dose of idelalisib when coadministering with moderate or strong CYP3A4 inducers has not been studied and thus no formal dose advice can be given.",(See Summary)
144,Idelalisib,Fluconazole,"
Potential Interaction
","
Very Low
","Coadministration has not been studied. Fluconazole is only metabolised to a minor extent. Idelalisib does not interfere with this metabolic pathway. However, fluconazole is an inhibitor of CYP3A4 and may increase concentrations of idelalisib. However, no clinically relevant interaction is expected since therapeutic levels of fluconazole are approximately 8-fold lower than the observed IC50s for CYP3A4. However, this possibility cannot be discarded in at-risk patients (e.g. hepatically impaired patients). Since the therapeutic index of idelalisib is relatively large, no a priori dose adjustment is necessary but monitoring for toxicity is recommended.",(See Summary)
145,Idelalisib,Flucytosine,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Flucytosine is metabolised to 5-fluorouracil (5-FU). 5-FU is further metabolised by dihydropyrimidine dehydrogenase (DPD) to an inactive metabolite. Idelalisib does not interfere with this elimination pathway. However, 5-FU binds to the enzyme thymidylate synthase resulting in DNA damage. This mechanism occurs in all fast dividing cells including bone marrow cells, resulting in haematological toxicity. Idelalisib also induces haematological toxicity which could be enhanced by the use of flucytosine. Due to the risk of additive haematological toxicity, haematological parameters should be monitored if coadministered.",(See Summary)
146,Idelalisib,Fludrocortisone,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied and should be avoided. Fludrocortisone is metabolised in the liver to inactive metabolites, possibly via CYP3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may increase concentrations of fludrocortisone. Therefore, coadministration should be avoided. If coadministration is clinically necessary, close monitoring or dose titration is recommended.",(See Summary)
147,Idelalisib,Flunitrazepam,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied and should be avoided. Flunitrazepam is metabolised mainly via CYP3A4 and CYP2C19. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of flunitrazepam. Therefore, coadministration should be avoided. If coadministration is clinically necessary, close monitoring or dose titration is recommended.",(See Summary)
148,Idelalisib,Fluoxetine,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Fluoxetine is metabolised by CYP2D6, CYP2C9 and to a lesser extent by CYP2C19 and CYP3A4 to form norfluoxetine. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may increase concentrations of fluoxetine. As the clinical relevance of this interaction is unknown, monitoring for toxicity may be required.",(See Summary)
149,Idelalisib,Fluphenazine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fluphenazine is metabolised by CYP2D6. Idelalisib does not inhibit or induce CYP2D6.  ,(See Summary)
150,Idelalisib,Flurazepam,"
Do Not Coadminister
","
Low
","Coadministration has not been studied and should be avoided. The metabolism of flurazepam is most likely CYP-mediated. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of flurazepam. Therefore, coadministration should be avoided. If coadministration is clinically necessary, close monitoring for flurazepam toxicity and a dose reduction of flurazepam should be considered.",(See Summary)
151,Idelalisib,Fluticasone,"
Do Not Coadminister
","
Low
","Coadministration has not been studied and should be avoided. Fluticasone is metabolised by CYP3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of fluticasone. Therefore, coadministration should be avoided. If coadministration is clinically necessary, close monitoring for fluticasone toxicity is recommended.",(See Summary)
152,Idelalisib,Fluvastatin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fluvastatin is mainly metabolised by CYP2C9. Idelalisib does not inhibit or induce CYP2C9. ,(See Summary)
153,Idelalisib,Fluvoxamine,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Fluvoxamine is metabolised mainly by CYP2D6 and to a lesser extent by CYP1A2. Idelalisib does not inhibit or induce CYP2D6 or CYP1A2. However, fluvoxamine is an inhibitor of CYP3A4 and may increase concentrations of idelalisib. Since the therapeutic index of idelalisib is relatively large, no a priori dose adjustment is necessary but monitoring for toxicity is recommended. ",(See Summary)
154,Idelalisib,Fondaparinux,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fondaparinux does not undergo cytochrome metabolism and is predominantly renally excreted. Idelalisib does not interact with this metabolic or elimination pathway.,(See Summary)
155,Idelalisib,Formoterol,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Formoterol is eliminated primarily by direct glucuronidation, with O-demethylation (by CYPs 2D6, 2C19, 2C9, and 2A6) followed by further glucuronidation. As multiple CYP450 and UGT enzymes catalyse the transformation the potential for a pharmacokinetic interaction is low.",(See Summary)
156,Idelalisib,Fosaprepitant,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied but should be avoided. Fosaprepitant is rapidly, almost completely, converted to the active metabolite aprepitant. Idelalisib does not interact with this metabolic pathway. Aprepitant is mainly metabolised by CYP3A4 and to a lesser extent by CYP1A2 and CYP2C19. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase aprepitant exposure, thus prolonging and increasing aprepitant therapeutic activity and adverse reactions. Therefore, coadministration should be avoided. If coadministration is clinically necessary, monitor closely for aprepitant toxicity. Furthermore, during treatment aprepitant is a moderate inhibitor of CYP3A4 and may increase idelalisib concentrations. Since the therapeutic index of idelalisib is relatively large, it is not necessary to decrease the idelalisib dose a priori. However, close monitoring for toxicity is recommended. After treatment, aprepitant is a weak inducer of CYP3A4, CYP2C9 and UGT. Concentrations of idelalisib may decrease due to weak induction of CYP3A4, but this is not considered to be clinically relevant.",(See Summary)
157,Idelalisib,Fosphenytoin,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied but should be avoided. Fosphenytoin is rapidly converted to the active metabolite phenytoin. Phenytoin is mainly metabolised by CYP2C9 and to a lesser extent by CYP2C19. Idelalisib is an inducer of CYP2C9 and CYP2C19 in vitro but the in vivo effect has yet to be confirmed. Furthermore, phenytoin is a potent inducer of CYP3A4, UGT and P-gp. Concentrations of idelalisib may decrease significantly due to induction of CYP3A4 and P-gp. Therefore, coadministration should be avoided, since a decrease in exposure can lead to decreased efficacy. Selection of an alternative concomitant medication with no or minimal enzyme or transporter induction potential is recommended. Increasing the dose of idelalisib when coadministering with moderate or strong CYP3A inducers has not been studied therefore no formal dose advice can be given.",(See Summary)
158,Idelalisib,Furosemide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Furosemide is glucuronidated mainly in the kidney (UGT1A9) and to a lesser extent in the liver (UGT1A1). A large proportion of furosemide is also eliminated unchanged renally (via OATs). In vitro data indicate that furosemide is an inhibitor of the renal transporters OAT1/OAT3. Idelalisib does not interact with this pathway.,(See Summary)
159,Idelalisib,Gabapentin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Gabapentin is cleared mainly by glomerular filtration. Idelalisib does not interfere with this elimination pathway.,(See Summary)
160,Idelalisib,Gemfibrozil,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Gemfibrozil is metabolised by UGT2B7. Idelalisib does not inhibit or induce UGT2B7. ,(See Summary)
161,Idelalisib,Gentamicin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Gentamicin is eliminated unchanged predominantly via glomerular filtration. Idelalisib does not interact with this elimination pathway. ,(See Summary)
162,Idelalisib,Gestodene,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Gestodene is metabolised by CYP3A4 and to a lesser extent by CYP2C9 and CYP2C19. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and idelalisib is an inducer of CYP2C9 and CYP2C19 in vitro. Concentrations of gestodene may increase due to inhibition of CYP3A4 but concentrations may decrease due to induction of CYP2C9 and CYP2C19. Although gestodene has a wide therapeutic window, the clinical relevance of this interaction is unknown and monitoring may be required. The SPC for idelalisib states that women using hormonal contraceptives should add a barrier method as a second form of contraception while taking idelalisib and for 1 month after stopping treatment, as it is currently unknown whether idelalisib may reduce the effectiveness.",(See Summary)
163,Idelalisib,Glibenclamide (Glyburide),"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied and should be avoided. Glibenclamide is mainly metabolised by CYP3A4 and to a lesser extent by CYP2C9. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of glibenclamide. Therefore, coadministration should be avoided. If coadministration is clinically necessary, close monitoring of blood glucose levels may be required.",(See Summary)
164,Idelalisib,Gliclazide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Gliclazide is metabolised mainly by CYP2C9 and to a lesser extent by CYP2C19. Idelalisib does not inhibit or induce CYP2C9 or CYP2C19. ,(See Summary)
165,Idelalisib,Glimepiride,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Glimepiride is mainly metabolised by CYP2C9. Idelalisib does not inhibit or induce CYP2C9. ,(See Summary)
166,Idelalisib,Glipizide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Glipizide is mainly metabolised by CYP2C9. Idelalisib does not inhibit or induce CYP2C9. ,(See Summary)
167,Idelalisib,Granisetron,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied and should be avoided. Granisetron is metabolised by CYP3A4 and is a substrate of P-gp. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of granisetron. Therefore, coadministration should be avoided. If coadministration is clinically necessary, close monitoring or dose titration is recommended. ",(See Summary)
168,Idelalisib,Grapefruit juice,"
Potential Interaction
","
Very Low
","Coadministration has not been studied. Grapefruit juice is known to inhibit CYP3A4 enzymes. Concentrations of idelalisib may increase due to inhibition of CYP3A4. Since the therapeutic index of idelalisib is relatively large, no a priori dose adjustment is necessary but close monitoring for toxicity is recommended.",(See Summary)
169,Idelalisib,Green tea,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. ,(See Summary)
170,Idelalisib,Griseofulvin,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied and should be avoided. Less than 1% of a griseofulvin dose is excreted unchanged via the kidneys. Idelalisib does not interfere with this elimination pathway. However, griseofulvin is a liver microsomal enzyme inducer and may lower plasma levels, and therefore reduce the efficacy, of concomitantly administered medicinal products metabolised by CYP3A4, such as idelalisib. Therefore, coadministration should be avoided as a decrease in exposure can lead to decreased efficacy. Selection of an alternative concomitant medication with no or minimal enzyme or transporter induction potential is recommended. Increasing the dose of idelalisib when coadministering with moderate or strong CYP3A inducers has not been studied and thus no formal dose advice can be given.",(See Summary)
171,Idelalisib,Haloperidol,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Haloperidol has a complex metabolism as it undergoes glucuronidation (UGTs 2B7>1A4 and 1A9), carbonyl reduction, as well as oxidative metabolism (CYP3A4 and CYP2D6). The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may increase concentrations of haloperidol. As the clinical relevance of this interaction is unknown, monitoring may be required. ",(See Summary)
172,Idelalisib,Heparin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Heparin is thought to be eliminated via the reticuloendothelial system. Idelalisib does not interact with this metabolic pathway.,(See Summary)
173,Idelalisib,Hydralazine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Hydralazine is metabolised via primary oxidative metabolism and acetylation. Although in vitro studies have suggested that hydralazine is a mixed enzyme inhibitor, which may weakly inhibit CYP3A4 and CYP2D6, it is not expected that this will lead to a clinical relevant interaction with idelalisib. ",(See Summary)
174,Idelalisib,Hydrochlorothiazide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Hydrochlorothiazide is not metabolised and is cleared by the kidneys via OAT1. In vitro data indicate that hydrochlorothiazide is unlikely to inhibit OAT1 in the range of clinically relevant drug concentrations. Significant interactions are not expected with idelalisib.,(See Summary)
175,Idelalisib,Hydrocodone,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied and should be avoided. Hydrocodone is metabolised by CYP2D6 to hydromorphone and by CYP3A4 to norhydrocodone, both of which have analgesic effects. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of hydrocodone. Therefore, coadministration should be avoided. If coadministration is clinically necessary, close monitoring for adverse reactions (e.g. respiratory depression, sedation) or dose titration is recommended.",(See Summary)
176,Idelalisib,Hydrocortisone (oral),"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied and should be avoided. Hydrocortisone is metabolised by CYP3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of hydrocortisone. Therefore, coadministration should be avoided. If coadministration is clinically necessary, close monitoring for hydrocortisone toxicity is recommended.",(See Summary)
177,Idelalisib,Hydrocortisone (topical),"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely with the topical use of hydrocortisone. ,(See Summary)
178,Idelalisib,Hydromorphone,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Hydromorphone is eliminated via glucuronidation, mainly by UGT2B7. Idelalisib does not inhibit or induce UGT2B7. ",(See Summary)
179,Idelalisib,Hydroxyurea (Hydroxycarbamide),"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Hydroxyurea is not a substrate of CYP enzymes or P-gp. However, due to the risk of additive haematological toxicity, haematological parameters should be monitored if coadministered.",(See Summary)
180,Idelalisib,Hydroxyzine,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Hydroxyzine is partly metabolised by alcohol dehydrogenase and partly by CYP3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may increase concentrations of hydroxyzine. Although hydroxyzine does not have a narrow therapeutic index and does have an alternative metabolic pathway, the clinical relevance of this is interaction is unknown and monitoring for toxicity may be required.  ",(See Summary)
181,Idelalisib,Ibandronic acid,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Ibandronic acid is not metabolised and is cleared from the plasma by uptake into bone and elimination via renal excretion. Although no pharmacokinetic interaction is expected, ibandronic acid should be taken after an overnight fast (at least 6 hours) and before the first food or drink of the day. Medicinal products and supplements should be similarly avoided prior to taking ibandronic acid. Fasting should be continued for at least 30 minutes after taking ibandronic acid. ",(See Summary)
182,Idelalisib,Ibuprofen,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ibuprofen is metabolised mainly by CYP2C9 and to a lesser extent by CYP2C8 and direct glucuronidation. Idelalisib is a weak inhibitor of CYP2C8. However, since ibuprofen has a wide therapeutic index, a clinically relevant interaction is unlikely.",(See Summary)
183,Idelalisib,Iloperidone,"
Potential Interaction
","
Very Low
","Coadministration has not been studied. Iloperidone is metabolised by CYP3A4 and CYP2D6. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of iloperidone. As the clinical relevance of this interaction is unknown, close monitoring for toxicity may be required.",(See Summary)
184,Idelalisib,Imipenem/Cilastatin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Imipenem and cilastatin are eliminated by glomerular filtration and to a lesser extent, active tubular secretion. Idelalisib does not interact with this elimination pathway. ",(See Summary)
185,Idelalisib,Imipramine,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Imipramine is metabolised by CYPs 3A4, 2C19 and 1A2 (minor) to desipramine. Imipramine and desipramine are both metabolised by CYP2D6. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may increase concentrations of imipramine. As multiple metabolic pathways play a role, no a priori dose adjustment of imipramine is necessary. As the clinical relevance of this interaction is unknown, monitoring for toxicity may be required.",(See Summary)
186,Idelalisib,Indapamide,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Indapamide is extensively metabolised by CYP450 (potentially via CYP3A4 and CYP2C19). The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may increase concentrations of indapamide. As the clinical relevance of this interaction is unknown, monitoring of blood pressure may be required.",(See Summary)
187,Idelalisib,Insulin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.,(See Summary)
188,Idelalisib,Interferon alpha,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Due to the risk of additive haematological toxicity, haematological parameters should be monitored if coadministered.",(See Summary)
189,Idelalisib,Interleukin 2 (Aldesleukin),"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Interleukin-2 is mainly eliminated by glomerular filtration. Idelalisib does not interfere with this elimination pathway.,(See Summary)
190,Idelalisib,Ipratropium bromide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. A small proportion of an inhaled ipratropium dose is systemically absorbed (6.9%). Metabolism is via ester hydrolysis and conjugation. Idelalisib does not interact with this metabolic pathway.,(See Summary)
191,Idelalisib,Irbesartan,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Irbesartan is metabolised by glucuronidation and oxidation (mainly CYP2C9). Idelalisib does not inhibit or induce CYP2C9 or UGTs.  ,(See Summary)
192,Idelalisib,Iron supplements,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. ,(See Summary)
193,Idelalisib,Isoniazid,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Isoniazid is acetylated in the liver to form acetylisoniazid which is then hydrolysed to isonicotinic acid and acetylhydrazine. Idelalisib does not interact with this metabolic pathway. ,(See Summary)
194,Idelalisib,Isosorbide dinitrate,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. In vitro studies suggest that CYP3A4 has a role in nitric oxide formation from isosorbide dinitrate. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may increase concentrations of isosorbide dinitrate. As the clinical relevance of this interaction is unknown, monitoring may be required. ",(See Summary)
195,Idelalisib,Itraconazole,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied and should be avoided. Itraconazole is an inhibitor of CYP3A4 and may increase concentrations of idelalisib. Since the therapeutic index of idelalisib is relatively large, no a priori dose adjustment is necessary but close monitoring for toxicity may be required. Furthermore, itraconazole is mainly metabolised by CYP3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of itraconazole. Therefore, coadministration should be avoided. If coadministration is clinically necessary, close monitoring for itraconazole toxicity is recommended. ",(See Summary)
196,Idelalisib,Ivabradine,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied and should be avoided. Ivabradine is metabolised by CYP3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of ivabradine. Therefore, coadministration should be avoided. If coadministration is clinically necessary, close monitoring of blood pressure or dose titration is recommended. ",(See Summary)
197,Idelalisib,Kanamycin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Kanamycin is eliminated unchanged predominantly via glomerular filtration. Idelalisib does not interact with this elimination pathway.,(See Summary)
198,Idelalisib,Ketoconazole,"
Do Not Coadminister
","
Low
","Coadministration should be avoided. Idelalisib concentrations may increase due to inhibition of CYP3A4 by ketoconazole. In healthy volunteers, coadministration of idelalisib (single dose of 400 mg) with ketoconazole (400 mg once daily for 4 days) increased idelalisib AUC and Cmax by 79% and 26%, respectively. Since the therapeutic index of idelalisib is relatively large, no a priori dose adjustment is necessary but close monitoring for toxicity is recommended. Furthermore, ketoconazole is metabolised by CYP3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of ketoconazole. Therefore, coadministration should be avoided. If coadministration is clinically necessary, close monitoring for ketoconazole toxicity is recommended. ",(See Summary)
199,Idelalisib,Labetalol,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Labetalol is mainly glucuronidated (via UGT1A1 and UGT2B7). Idelalisib does not inhibit or induce UGT1A1 or UGT2B7. ,(See Summary)
200,Idelalisib,Lacidipine,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied and should be avoided. Lacidipine is metabolised by CYP3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of lacidipine. Therefore, coadministration should be avoided. If coadministration is clinically necessary, close monitoring of therapeutic effect (blood pressure) and adverse reactions is recommended.",(See Summary)
201,Idelalisib,Lactulose,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metabolism of lactulose to lactic acid occurs via gastro-intestinal microbial flora only. ,(See Summary)
202,Idelalisib,Lansoprazole,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Lansoprazole is mainly metabolised by CYP2C19 and to lesser extent by CYP3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and idelalisib is an inducer of CYP2C19 in vitro. Concentrations of lansoprazole may increase due to inhibition of CYP3A4 but concentrations may decrease due to induction of CYP2C19. Although lansoprazole has a wide therapeutic index, the clinical relevance of this interaction is unlikely and monitoring for toxicity may be required. The solubility of idelalisib decreases with increasing pH of the stomach. However, in patients with chronic lymphoid leukaemia (CLL) and indolent non-Hodgkin lymphoma (iNHL), coadministration of idelalisib and acid-reducing agents did not demonstrate any clinically relevant effects. For patients with iNHL, idelalisib AUC and Cmax increased by 4% and 6%, respectively, whereas for patients with CLL, idelalisib AUC and Cmax decreased by 11% and 5%, respectively. Therefore, no clinically relevant interactions are expected. ",(See Summary)
203,Idelalisib,Lercanidipine,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied and should be avoided. Lercanidipine is mainly metabolised by CYP3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of lercanidipine. Therefore, coadministration should be avoided. If coadministration is clinically necessary, close monitoring of therapeutic effect (blood pressure) and adverse reactions is recommended.",(See Summary)
204,Idelalisib,Levocetirizine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Less than 14% of a dose of levocetirizine is metabolised. Levocetirizine is mainly eliminated unchanged in the urine through both glomerular filtration and tubular secretion. Idelalisib does not interfere with this elimination pathway. ,(See Summary)
205,Idelalisib,Levofloxacin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Levofloxacin is renally eliminated mainly by glomerular filtration and active secretion (possibly OCT2). Idelalisib does not interact with this elimination pathway. ,(See Summary)
206,Idelalisib,Levomepromazine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Levomepromazine is metabolised by CYP2D6. Idelalisib does not inhibit or induce CYP2D6.  ,(See Summary)
207,Idelalisib,Levonorgestrel,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Levonorgestrel is metabolised by CYP3A4 and is glucuronidated to a minor extent. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and idelalisib is an inducer of UGT in vitro. Concentrations of levonorgestrel may increase due to inhibition of CYP3A4 but concentrations may decrease due to induction of UGT. Although levonorgestrel has a wide therapeutic window, the clinical relevance of this interaction is unknown and monitoring may be required. The SPC for idelalisib states that women using hormonal contraceptives should add a barrier method as a second form of contraception while taking idelalisib and for 1 month after stopping treatment, as it is currently unknown whether idelalisib may reduce the effectiveness.",(See Summary)
208,Idelalisib,Levonorgestrel (Emergency Contraception),"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Levonorgestrel is metabolised by CYP3A4 and is glucuronidated to a minor extent. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and idelalisib is an inducer of UGT in vitro. Concentrations of levonorgestrel may increase due to inhibition of CYP3A4 but concentrations may decrease due to induction of UGT. Although levonorgestrel has a wide therapeutic window, the clinical relevance of this interaction is unknown and monitoring may be required. The SPC for idelalisib states that women using hormonal contraceptives should add a barrier method as a second form of contraception while taking idelalisib and for 1 month after stopping treatment, as it is currently unknown whether idelalisib may reduce the effectiveness.",(See Summary)
209,Idelalisib,Levothyroxine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Levothyroxine is metabolised by deiodination (by enzymes of deiodinase family) and glucuronidation. Idelalisib does not interfere with these pathways.,(See Summary)
210,Idelalisib,Lidocaine (Lignocaine),"
Potential Interaction
","
Very Low
","Coadministration has not been studied. CYP1A2 is the predominant enzyme involved in lidocaine metabolism in the range of therapeutic concentrations with a minor contribution from CYP3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of lidocaine. Therefore, coadministration should be avoided. If coadministration is unavoidable, close clinical monitoring or dose titration is recommended.",(See Summary)
211,Idelalisib,Linagliptin,"
Potential Interaction
","
Very Low
","Coadministration has not been studied. Linagliptin is mainly eliminated as parent compound in faeces with metabolism by CYP3A4 representing a minor elimination pathway. Linagliptin is also a substrate of P-gp. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and idelalisib is an inhibitor of P-gp in vitro. Since CYP3A4 mediated metabolism is only a minor pathway and systemic P-gp is involved, a clinically relevant interaction is unlikely. However, linagliptin is an inhibitor of CYP3A4 and may increase concentrations of idelalisib. Since the therapeutic index of idelalisib is relatively large, no a priori dose adjustment is necessary but close monitoring for toxicity is recommended.",(See Summary)
212,Idelalisib,Linezolid,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Linezolid undergoes non-CYP mediated metabolism. Idelalisib does not interact with this metabolic pathway.,(See Summary)
213,Idelalisib,Liraglutide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as liraglutide is degraded by endogenous endopeptidases. ,(See Summary)
214,Idelalisib,Lisinopril,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lisinopril is renally eliminated unchanged via glomerular filtration. Idelalisib does not interact with this elimination pathway.,(See Summary)
215,Idelalisib,Lithium,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lithium is mainly eliminated unchanged in the kidneys. Lithium is freely filtered at a rate that is dependent upon the glomerular filtration rate therefore no pharmacokinetic interaction is expected. ,(See Summary)
216,Idelalisib,Live vaccines,"
Do Not Coadminister
","
Very Low
","Coadministration of live vaccines (such as BCG vaccine; measles, mumps and rubella vaccines; varicella vaccines; typhoid vaccines; rotavirus vaccines; yellow fever vaccines; oral polio vaccine) has not been studied. In patients who are receiving cytotoxics or other immunosuppressant drugs, use of live vaccines for immunisation is contraindicated. If coadministration is judged clinically necessary, use with extreme caution since generalized infections can occur.",(See Summary)
217,Idelalisib,Loperamide,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied and should be avoided. Loperamide is mainly metabolised by CYP3A4 and CYP2C8. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and idelalisib is an inhibitor of CYP2C8 in vitro. Concentrations of loperamide may significantly increase due to inhibition of CYP3A4 and CYP2C8. Therefore, coadministration should be avoided. If coadministration is clinically necessary, close monitoring or dose titration is recommended. ",(See Summary)
218,Idelalisib,Loratadine,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied and should be avoided. Loratadine is metabolised mainly by CYP3A4 and to a lesser extent by CYP2D6. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of loratadine. Therefore, coadministration should be avoided. If coadministration is clinically necessary, close monitoring or dose titration is recommended. ",(See Summary)
219,Idelalisib,Lorazepam,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lorazepam is eliminated by non-CYP mediated pathways and no effect on plasma concentrations is expected when coadministered with idelalisib. ,(See Summary)
220,Idelalisib,Lormetazepam,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lormetazepam is mainly glucuronidated. Idelalisib does not interact with this metabolic pathway. ,(See Summary)
221,Idelalisib,Losartan,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Losartan is converted to its active metabolite mainly by CYP2C9 in the range of clinical concentrations. Idelalisib does not inhibit or induce CYP2C9. ,(See Summary)
222,Idelalisib,Lovastatin,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied and should be avoided. Lovastatin is metabolised by CYP3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of lovastatin. Therefore, coadministration should be avoided. Replacement of lovastatin with pravastatin or rosuvastatin should be considered.",(See Summary)
223,Idelalisib,Macitentan,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied and should be avoided. Macitentan is metabolised mainly by CYP3A4 and to a lesser extent by CYPs 2C19, 2C9 and 2C8. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and idelalisib is an inhibitor of CYP2C8 in vitro. Concentrations of macitentan may significantly increase due to inhibition of CYP3A4 and CYP2C8. Therefore, coadministration should be avoided. If coadministration of a CYP3A4 substrate is clinically necessary, close monitoring or dose titration is recommended. ",(See Summary)
224,Idelalisib,Magnesium,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Magnesium is eliminated in the kidney, mainly by glomerular filtration. Idelalisib does not interfere with this elimination pathway. ",(See Summary)
225,Idelalisib,Maprotiline,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Maprotiline is mainly metabolised by CYP2D6. Idelalisib does not inhibit or induce CYP2D6. ,(See Summary)
226,Idelalisib,Medroxyprogesterone (depot),"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Medroxyprogesterone is metabolised by CYP3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may increase concentrations of medroxyprogesterone. Although medroxyprogesterone has a wide therapeutic window, the clinical relevance of this interaction is unknown and monitoring may be required. The SPC for idelalisib states that women using hormonal contraceptives should add a barrier method as a second form of contraception while taking idelalisib and for 1 month after stopping treatment, as it is currently unknown whether idelalisib may reduce the effectiveness.",(See Summary)
227,Idelalisib,Medroxyprogesterone (non-depot),"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Medroxyprogesterone is metabolised by CYP3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may increase concentrations of medroxyprogesterone. Although medroxyprogesterone has a wide therapeutic window, the clinical relevance of this interaction is unknown and monitoring may be required. The SPC for idelalisib states that women using hormonal contraceptives should add a barrier method as a second form of contraception while taking idelalisib and for 1 month after stopping treatment, as it is currently unknown whether idelalisib may reduce the effectiveness.",(See Summary)
228,Idelalisib,Mefenamic acid,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mefenamic acid is metabolised by CYP2C9 and glucuronidated by UGT2B7 and UGT1A9. Idelalisib does not inhibit or induce CYP2C9, UGT2B7 or UGT1A9.",(See Summary)
229,Idelalisib,Megestrol acetate,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Megestrol acetate is mainly eliminated in the urine. ,(See Summary)
230,Idelalisib,Meropenem,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Meropenem is primarily eliminated by the kidney with in vitro data suggesting it is a substrate of the renal transporters OAT3>OAT1. Idelalisib does not interfere with this elimination pathway. ,(See Summary)
231,Idelalisib,Mesalazine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mesalazine is metabolised to N-acetyl-mesalazine by N-acetyltransferase. Idelalisib does not interfere with this pathway. ,(See Summary)
232,Idelalisib,Metamizole,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied and should be avoided. Metamizole is metabolised by CYP3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of metamizole. Therefore, coadministration should be avoided. If coadministration is clinically necessary, close monitoring for adverse reactions or dose titration is recommended. Furthermore, metamizole is a weak inducer of CYP3A4 and may decrease concentrations of idelalisib. A decrease in idelalisib exposure can lead to decreased efficacy. The clinical relevance of this interaction is unknown and selection of an alternative concomitant medication with no or minimal enzyme or transporter induction potential is recommended. ",(See Summary)
233,Idelalisib,Metformin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metformin is mainly eliminated unchanged in the urine (via OCT2). Idelalisib does not interact with this elimination pathway.,(See Summary)
234,Idelalisib,Methadone,"
Do Not Coadminister
","
Low
","Coadministration has not been studied and should be avoided. Methadone is demethylated by CYP3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of methadone. Therefore, coadministration should be avoided. If coadministration is clinically necessary, close monitoring for adverse reactions (e.g. respiratory depression, sedation) or dose titration is recommended.",(See Summary)
235,Idelalisib,Methyldopa,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Methyldopa is excreted in urine largely by glomerular filtration, primarily unchanged and as the mono-O-sulfate conjugate. It is unlikely to affect the disposition of idelalisib, or to be altered by coadministration with idelalisib.",(See Summary)
236,Idelalisib,Methylphenidate,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Methylphenidate is not metabolised by CYP450 to a clinically relevant extent and does not inhibit or induce CYP450s. ,(See Summary)
237,Idelalisib,Methylprednisolone,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied and should be avoided. Methylprednisolone is metabolised by CYP3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of methylprednisolone. Therefore, coadministration should be avoided. If coadministration is clinically necessary, close monitoring for methylprednisolone toxicity is recommended.",(See Summary)
238,Idelalisib,Metoclopramide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metoclopramide is partially metabolised by the CYP450 system (mainly CYP2D6). Idelalisib does not inhibit or induce CYP2D6.,(See Summary)
239,Idelalisib,Metolazone,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as metolazone is largely excreted unchanged in the urine. ,(See Summary)
240,Idelalisib,Metoprolol,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metoprolol is mainly metabolised by CYP2D6. Idelalisib does not inhibit or induce CYP2D6.,(See Summary)
241,Idelalisib,Metronidazole,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but elevated plasma concentrations have been reported for some CYP3A substrates (e.g. tacrolimus, ciclosporin) with metronidazole. However, metronidazole did not increase concentrations of several CYP3A probe drugs (e.g. midazolam, alprazolam). Since the mechanism of the interaction with CYP3A has not yet been identified, an interaction with idelalisib cannot be excluded. As the therapeutic index of idelalisib is relatively large, no a priori dose adjustment is necessary but close monitoring for toxicity is recommended.",(See Summary)
242,Idelalisib,Mexiletine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mexiletine is metabolised mainly by CYP2D6 and to a lesser extent by CYP1A2. Idelalisib does not inhibit or induce CYP2D6 or CYP1A2. ,(See Summary)
243,Idelalisib,Mianserin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mianserin is metabolised by CYP2D6, CYP1A2 and to a lesser extent by CYP3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4. However, a clinical relevant interaction is unlikely as CYP3A4-mediated metabolism is only a minor pathway.",(See Summary)
244,Idelalisib,Miconazole,"
Potential Interaction
","
Very Low
","Coadministration has not been studied. Miconazole is metabolised via O-dealkylation and oxidative N-dealkylation, potentially CYP-mediated. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may increase concentrations of miconazole. As the clinical relevance of this interaction is unknown, monitoring may be required. Furthermore, miconazole is an inhibitor of CYP3A4 and may increase idelalisib concentrations (especially oromucosal coadministration). Since the therapeutic index of idelalisib is relatively large, no a priori dose adjustment is necessary but close monitoring for toxicity is recommended. ",(See Summary)
245,Idelalisib,Midazolam (oral),"
Do Not Coadminister
","
Moderate
","Coadministration should be avoided. Midazolam is metabolised by CYP3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of midazolam. In healthy volunteers (n=12), coadministration of oral midazolam (single dose of 5 mg) and idelalisib (150 mg twice daily for 10 days) increased midazolam AUC and Cmax by 437% and 138%, respectively. Therefore, coadministration should be avoided. Replacement of midazolam with an alternative sedative agent, such as temazepam, nitrazepam or lorazepam should be considered. ",(See Summary)
246,Idelalisib,Midazolam (parenteral),"
Do Not Coadminister
","
Low
","Coadministration has not been studied and should be avoided. Midazolam is metabolised by CYP3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of midazolam. In healthy volunteers (n=12), coadministration of oral midazolam (single dose of 5 mg) and idelalisib (150 mg twice daily for 10 days) increased midazolam AUC and Cmax by 437% and 138%, respectively. Therefore, coadministration should be avoided. Replace midazolam with an alternative sedative agent, such as temazepam, nitrazepam or lorazepam.",(See Summary)
247,Idelalisib,Milnacipran,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Milnacipran is mainly eliminated unchanged (50%), and as glucuronides (30%) and oxidative metabolites (20%). Idelalisib is unlikely to interfere with these pathways.",(See Summary)
248,Idelalisib,Mirtazapine,"
Potential Interaction
","
Very Low
","Coadministration has not been studied. Mirtazapine is metabolised to 8-hydroxymirtazapine by CYP2D6 and CYP1A2, and mainly by CYP3A4 to N-desmethylmirtazapine. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may increase concentrations of mirtazapine. As the clinical relevance of this interaction is unknown, close monitoring of mirtazapine plasma concentrations in addition to toxicity should be considered, if available. ",(See Summary)
249,Idelalisib,Mometasone,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied and should be avoided. Mometasone is metabolised by CYP3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of mometasone. Therefore, coadministration should be avoided. If coadministration is clinically necessary, close monitoring for mometasone toxicity is recommended.",(See Summary)
250,Idelalisib,Montelukast,"
Potential Interaction
","
Very Low
","Coadministration has not been studied. Montelukast is mainly metabolised by CYP2C8 and to a lesser extent by CYPs 3A4 and 2C9. Idelalisib is an inhibitor of CYP2C8 in vitro and the primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4. Furthermore, idelalisib is an inducer of CYP2C9 in vitro but the in vivo effect has yet to be determined. Concentrations of montelukast may increase due to inhibition of CYP2C8 and CYP3A4 but concentrations may decrease due to induction of CYP2C9. As the clinical relevance of this interaction is unknown, close monitoring for toxicity may be required. ",(See Summary)
251,Idelalisib,Morphine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Morphine is mainly glucuronidated to morphine-3-glucuronide (UGT2B7>UGT1A1) and to a lesser extent, to the pharmacologically active morphine-6-glucuronide (UGT2B7>UGT1A1). Idelalisib does not inhibit or induce UGTs. ",(See Summary)
252,Idelalisib,Moxifloxacin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Moxifloxacin is predominantly glucuronidated by UGT1A1. Idelalisib does not inhibit or induce UGT1A1. ,(See Summary)
253,Idelalisib,Mycophenolate,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Mycophenolate is mainly glucuronidated by UGT1A9 and UGT2B7. Idelalisib is an inducer of UGT in vitro but the in vivo effect has yet to be determined. As the clinical relevance of this interaction is unknown, monitoring may be required. Due to the risk of additive haematological toxicity, haematological parameters should be monitored if coadministered.",(See Summary)
254,Idelalisib,Nadroparin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nadroparin is renally excreted by a nonsaturable mechanism. Idelalisib does not interact with this elimination pathway.,(See Summary)
255,Idelalisib,Nandrolone,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nandrolone is metabolised in the liver by alpha-reductase. Idelalisib does not interact with this pathway.,(See Summary)
256,Idelalisib,Naproxen,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Naproxen is mainly glucuronidated by UGT2B7 (major) and demethylated to desmethylnaproxen by CYP2C9 (major) and CYP1A2. Idelalisib does not inhibit or induce these CYPs and UGTs. ,(See Summary)
257,Idelalisib,Nateglinide,"
Potential Interaction
","
Very Low
","Coadministration has not been studied. Nateglinide is mainly metabolised by CYP2C9 (70%) and to a lesser extent by CYP3A4 (30%). The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may increase concentrations of nateglinide. As the clinical relevance of this interaction is unknown, close monitoring of blood glucose levels may be required.",(See Summary)
258,Idelalisib,Nebivolol,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nebivolol metabolism involves CYP2D6. Idelalisib does not inhibit or induce CYP2D6.,(See Summary)
259,Idelalisib,Nefazodone,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied and is not recommended. Nefazodone is an inhibitor of CYP3A4 and may increase concentrations of idelalisib. Since the therapeutic index of idelalisib is relatively large, no a priori dose adjustment is necessary. However, close monitoring for toxicity is recommended. Furthermore, nefazodone is metabolised mainly by CYP3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of nefazodone. Therefore, coadministration should be avoided. If coadministration is clinically necessary, close monitoring or dose titration is recommended. ",(See Summary)
260,Idelalisib,Nicardipine,"
Do Not Coadminister
","
Low
","Coadministration has not been studied and should be avoided. Nicardipine is metabolised mainly by CYP3A4 and to a lesser extent by CYP2D6 and CYP2C8. Idelalisib is an inhibitor of CYP2C8 in vitro and the primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4. Concentrations of nicardipine may significantly increase due to inhibition of CYP3A4 and CYP2C8. Therefore, coadministration should be avoided. If coadministration is clinically necessary, close monitoring of therapeutic effect (blood pressure) and adverse reactions is recommended. ",(See Summary)
261,Idelalisib,Nicotinamide (Niacinamide),"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nicotinamide is converted to N-methylnicotinamide by nicotinamide methyltransferase which in turn is metabolised by xanthine oxidase and aldehyde oxidase. Idelalisib does not interact with this metabolic pathway. In addition, nicotinic acid and its metabolites do not inhibit CYP-mediated reactions in vitro and therefore are unlikely to impact idelalisib exposure.",(See Summary)
262,Idelalisib,Nifedipine,"
Do Not Coadminister
","
Low
","Coadministration has not been studied and should be avoided. Nifedipine is metabolised mainly by CYP3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of nifedipine. Therefore, coadministration should be avoided. If coadministration is clinically necessary, close monitoring of therapeutic effect (blood pressure) and adverse reactions is recommended.",(See Summary)
263,Idelalisib,Nimesulide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nimesulide is extensively metabolised in the liver following multiple pathways including CYP2C9. Idelalisib does not interact with this pathway. ,(See Summary)
264,Idelalisib,Nisoldipine,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied and should be avoided. Nisoldipine is metabolised by CYP3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of nisoldipine. Therefore, coadministration should be avoided. If coadministration is clinically necessary, close monitoring of therapeutic effect (blood pressure) and adverse reactions is recommended.",(See Summary)
265,Idelalisib,Nitrendipine,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied and should be avoided. Nitrendipine is extensively metabolised mainly by CYP3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of nitrendipine. Therefore, coadministration should be avoided. If coadministration is clinically necessary, close monitoring of therapeutic effect (blood pressure) and adverse reactions is recommended.",(See Summary)
266,Idelalisib,Nitrofurantoin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nitrofurantoin is partly metabolised in the liver via glucuronidation and N-acetylation and partly eliminated in the urine as unchanged drug (30-40%). Idelalisib does not interact with these metabolic or elimination pathways. ,(See Summary)
267,Idelalisib,Norelgestromin,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Norelgestromin is metabolised to norgestrel (possibly by CYP3A4). The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may increase concentrations of norelgestromin. Although CYP3A4 mediated metabolism is only a minor pathway and norelgestromin has a wide therapeutic index, the clinical relevance of this is interaction is unknown and monitoring for toxicity may be required. The SPC for idelalisib states that women using hormonal contraceptives should add a barrier method as a second form of contraception while taking idelalisib and for 1 month after stopping treatment, as it is currently unknown whether idelalisib may reduce the effectiveness.",(See Summary)
268,Idelalisib,Norethisterone (Norethindrone),"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Norethisterone is extensively biotransformed, first by reduction and then by sulfate and glucuronide conjugation. Idelalisib is an inducer of UGT in vitro but the in vivo effect has yet to be determined. As the clinical relevance of this interaction is unknown, monitoring may be required. The SPC for idelalisib states that women using hormonal contraceptives should add a barrier method as a second form of contraception while taking idelalisib and for 1 month after stopping treatment, as it is currently unknown whether idelalisib may reduce the effectiveness. ",(See Summary)
269,Idelalisib,Norgestimate,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Norgestimate is rapidly deacetylated to the active metabolite which is further metabolised via CYP450. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may increase concentrations of norgestimate. Although CYP3A4 mediated metabolism is only a minor pathway and norgestimate has a wide therapeutic window, the clinical relevance of this is interaction is unknown and monitoring for toxicity may be required. The SPC for idelalisib states that women using hormonal contraceptives should add a barrier method as a second form of contraception while taking idelalisib and for 1 month after stopping treatment, as it is currently unknown whether idelalisib may reduce the effectiveness.",(See Summary)
270,Idelalisib,Norgestrel,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Norgestrel is a racemic mixture with levonorgestrel being biologically active. Levonorgestrel is mainly metabolised by CYP3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may increase concentrations of levonorgestrel. Although levonorgestrel has a wide therapeutic window, the clinical relevance of this interaction is unknown and monitoring may be required. The SPC for idelalisib states that women using hormonal contraceptives should add a barrier method as a second form of contraception while taking idelalisib and for 1 month after stopping treatment, as it is currently unknown whether idelalisib may reduce the effectiveness.",(See Summary)
271,Idelalisib,Nortriptyline,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nortriptyline is metabolised mainly by CYP2D6. Idelalisib does not inhibit or induce CYP2D6.,(See Summary)
272,Idelalisib,Nystatin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Systemic absorption of nystatin from oral or topical dosage forms is not significant, therefore no drug interactions are expected. ",(See Summary)
273,Idelalisib,Ofloxacin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ofloxacin is renally eliminated unchanged by glomerular filtration and active tubular secretion via both cationic and anionic transport systems. Idelalisib is unlikely to interfere with these pathways.,(See Summary)
274,Idelalisib,Olanzapine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Olanzapine is metabolised mainly by CYP1A2 and CYP2D6, but also by glucuronidation (UGT1A4). Idelalisib does not inhibit or induce CYP1A2, CYP2D6 or UGT1A4. ",(See Summary)
275,Idelalisib,Olmesartan,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Olmesartan medoxomil is de-esterified to the active metabolite olmesartan which is eliminated in the faeces and urine. ,(See Summary)
276,Idelalisib,Omeprazole,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Omeprazole is mainly metabolised by CYP2C19 and to lesser extent by CYP3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and idelalisib is an inducer of CYP2C19 in vitro. Concentrations of omeprazole may increase due to inhibition of CYP3A4 but concentrations may decrease due to induction of CYP2C19. Although omeprazole has a wide therapeutic index, the clinical relevance of this interaction is unknown and monitoring for toxicity may be required. The solubility of idelalisib decreases with increasing pH of the stomach. However, in patients with chronic lymphoid leukaemia (CLL) and indolent non-Hodgkin lymphoma (iNHL), coadministration of idelalisib and acid-reducing agents did not demonstrate any clinically relevant effects. For patients with iNHL, idelalisib AUC and Cmax increased by 4% and 6%, respectively, whereas for patients with CLL, idelalisib AUC and Cmax decreased by 11% and 5%, respectively. Therefore, no clinically relevant interactions are expected.",(See Summary)
277,Idelalisib,Ondansetron,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied and should be avoided. Ondansetron is metabolised mainly by CYP1A2 and CYP3A4 and to a lesser extent by CYP2D6. Ondansetron is also a substrate of P-gp. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of ondansetron. Therefore, coadministration should be avoided. If coadministration is clinically necessary, close monitoring or dose titration is recommended. ",(See Summary)
278,Idelalisib,Oxazepam,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Oxazepam is mainly glucuronidated. Idelalisib does not interact with this metabolic pathway. ,(See Summary)
279,Idelalisib,Oxcarbazepine,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied and should be avoided. Oxcarbazepine is metabolised by CYP3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of oxcarbazepine. Therefore, coadministration should be avoided. If coadministration is clinically necessary, close monitoring of oxcarbazepine plasma concentrations is recommended. Furthermore, oxcarbazepine is an inducer of CYP3A4 and may significantly decrease concentrations of idelalisib. Coadministration should be avoided as a decrease in idelalisib exposure can lead to decreased efficacy. Selection of an alternative concomitant medication with no or minimal enzyme or transporter induction potential is recommended. Increasing the dose of idelalisib when coadministering with moderate or strong CYP3A inducers has not been studied and thus no formal dose advice can be given. ",(See Summary)
280,Idelalisib,Oxprenolol,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Oxprenolol is largely metabolised via glucuronidation. Idelalisib does not inhibit or induce UGTs.,(See Summary)
281,Idelalisib,Oxycodone,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied and should be avoided. Oxycodone is metabolised principally to noroxycodone via CYP3A4 and oxymorphone via CYP2D6. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of oxycodone. Therefore, coadministration should be avoided. If coadministration is clinically necessary, close monitoring for adverse reactions (e.g. respiratory depression, sedation) or dose titration is recommended.",(See Summary)
282,Idelalisib,Paliperidone,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Paliperidone is primarily renally eliminated (possibly via OCT) with minimal metabolism occurring via CYP2D6 and CYP3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may increase concentrations of paliperidone. Although CYP3A4 mediated metabolism is only a minor pathway, the clinical relevance of this is interaction is unknown and monitoring may be required.",(See Summary)
283,Idelalisib,Palonosetron,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied and should be avoided. Palonosetron is metabolised mainly by CYP2D6 and to a lesser extent by CYP3A4 and CYP1A2. Palonosetron is also a substrate of P-gp. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and idelalisib is an inhibitor of P-gp in vitro and may significantly increase concentrations of palonosetron. Therefore, coadministration should be avoided. If coadministration is clinically necessary, close monitoring or dose titration is recommended.",(See Summary)
284,Idelalisib,Pamidronic acid,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as pamidronic acid is not metabolised and is cleared as unchanged drug via urine.,(See Summary)
285,Idelalisib,Pantoprazole,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Pantoprazole is mainly metabolised by CYP2C19 and to a lesser extent by CYPs 3A4, 2D6 and 2C9. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and idelalisib is an inducer of CYP2C9 and CYP2C19 in vitro. Concentrations of pantoprazole may increase due to inhibition of CYP3A4 but concentrations may decrease due to induction of CYP2C9 and CYP2C19. Although pantoprazole has a wide therapeutic index, the clinical relevance of this interaction is unknown and monitoring for toxicity may be required. The solubility of idelalisib decreases with increasing pH of the stomach. However, in patients with chronic lymphoid leukaemia (CLL) and indolent non-Hodgkin lymphoma (iNHL), coadministration of idelalisib and acid-reducing agents did not demonstrate any clinically relevant effects. For patients with iNHL, idelalisib AUC and Cmax increased by 4% and 6%, respectively, whereas for patients with CLL, idelalisib AUC and Cmax decreased by 11% and 5%, respectively. Therefore, no clinically relevant interactions are expected.",(See Summary)
286,Idelalisib,Para-aminosalicylic acid,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Para-aminosalicylic acid and its acetylated metabolite are mainly excreted in the urine by glomerular filtration and tubular secretion. Idelalisib does not interact with this elimination pathway. ,(See Summary)
287,Idelalisib,Paracetamol (Acetaminophen),"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Paracetamol is mainly metabolised by glucuronidation (via UGTs 1A9 (major), 1A6, 1A1 and 2B15), sulfation, and to a lesser extent by oxidation (CYPs 2E1 (major), 1A2, 3A4 and 2D6). There is no evidence that idelalisib inhibits or induces UGT1A9 and CYP2E1. ",(See Summary)
288,Idelalisib,Paroxetine,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied and should be avoided. Paroxetine is mainly metabolised by CYP2D6 and CYP3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of paroxetine. Therefore, coadministration should be avoided. If coadministration is clinically necessary, close monitoring or dose titration is recommended. ",(See Summary)
289,Idelalisib,Peginterferon alfa-2a,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Due to the risk of additive haematological toxicity, haematological parameters should be monitored if coadministered.",(See Summary)
290,Idelalisib,Penicillins,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Penicillins are mainly eliminated in the urine (20% by glomerular filtration and 80% by tubular secretion via OAT). Idelalisib does not interfere with the elimination of penicillins.,(See Summary)
291,Idelalisib,Perazine,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied and should be avoided. Perazine is demethylated via CYP3A4 and to a lesser extent by CYP2C9, with oxidation via FMO3. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of perazine. Therefore, coadministration should be avoided. If coadministration is clinically necessary, close monitoring or dose titration is recommended. ",(See Summary)
292,Idelalisib,Periciazine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. The metabolism of periciazine has not been well characterized but is likely to involve CYP2D6. Idelalisib does not inhibit or induce CYP2D6. ,(See Summary)
293,Idelalisib,Perindopril,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied and should be avoided. Perindopril is hydrolysed to the active metabolite perindoprilat probably via CYP3A4 and is metabolised to other inactive metabolites. Elimination occurs predominantly via the urine. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of perindopril. Therefore, coadministration should be avoided. If coadministration is clinically necessary, close monitoring or dose titration is recommended. ",(See Summary)
294,Idelalisib,Perphenazine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Perphenazine is metabolised by CYP2D6. Idelalisib does not inhibit or induce CYP2D6. ,(See Summary)
295,Idelalisib,Pethidine (Meperidine),"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Pethidine is metabolised mainly by CYP2B6 and to a lesser extent by CYP3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may increase concentrations of pethidine. Although CYP3A4 mediated metabolism is only a minor metabolic pathway, the clinical relevance of this interaction is unknown and monitoring for toxicity may be required.",(See Summary)
296,Idelalisib,Phenelzine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Phenelzine is primarily metabolised by oxidation via monoamine oxidase and to a lesser extent by acetylation. Idelalisib does not interact with these metabolic pathways.,(See Summary)
297,Idelalisib,Phenobarbital (Phenobarbitone),"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied and should be avoided. Phenobarbital is partially metabolised in the liver by CYP2C19. Idelalisib is an inducer of CYP2C19 in vitro but the in vivo effect has yet to be determined. The clinical relevance of this interaction is unknown and caution is advised with coadministering idelalisib with CYP2C19 substrates, such as phenobarbital, that have a narrow therapeutic index. Furthermore, phenobarbital is an inducer of CYP3A4 and may significantly decrease concentrations of idelalisib. Coadministration should be avoided as a decrease in idelalisib exposure can lead to decreased efficacy. Selection of an alternative concomitant medication with no or minimal enzyme or transporter induction potential is recommended. Increasing the dose of idelalisib when coadministering with moderate or strong CYP3A inducers has not been studied and thus no formal dose advice can be given. ",(See Summary)
298,Idelalisib,Phenprocoumon,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied but should be avoided. Phenprocoumon is mainly metabolised by CYP2C9 and CYP3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of phenprocoumon. Therefore, coadministration should be avoided. Patients who require anticoagulation should receive low-molecular-weight or standard heparin, instead of coumarin derivatives.",(See Summary)
299,Idelalisib,Phenytoin,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied but is contraindicated. Phenytoin is mainly metabolised by CYP2C9 and to a lesser extent by CYP2C19. Idelalisib is an inducer of CYP2C9 and CYP2C19 in vitro but the in vivo effect has yet to be confirmed. Furthermore, phenytoin is a potent inducer of CYP3A4, UGT and P-gp. Concentrations of idelalisib may decrease significantly due to induction of CYP3A4 and P-gp. Therefore, coadministration should be avoided, since a decrease in exposure can lead to decreased efficacy. Selection of an alternative concomitant medication with no or minimal enzyme or transporter induction potential is recommended. Increasing the dose of idelalisib when coadministering with moderate or strong CYP3A inducers has not been studied therefore no formal dose advice can be given.",(See Summary)
300,Idelalisib,Phytomenadione (Vitamin K),"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. An in vitro study found that the only CYP450 enzyme involved in phytomenadione metabolism was CYP4F2. Idelalisib does not inhibit or induce CYP4F2. ,(See Summary)
301,Idelalisib,Pimozide,"
Do Not Coadminister
","
Low
","Coadministration has not been studied and should be avoided. Pimozide is mainly metabolised by CYP3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of pimozide. Therefore, coadministration should be avoided. Alternative antipsychotics, such as olanzapine, may be considered. ",(See Summary)
302,Idelalisib,Pindolol,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pindolol is partly metabolised to hydroxymetabolites (possibly via CYP2D6) and partly eliminated unchanged in the urine. Idelalisib does not interfere with these metabolic and elimination pathways.,(See Summary)
303,Idelalisib,Pioglitazone,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Pioglitazone is metabolised mainly by CYP2C8 and to a lesser extent by CYPs 3A4, 1A2 and 2C9. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and idelalisib is an inhibitor of CYP2C8 in vitro. Idelalisib is also an inducer of CYP2C9 in vitro. Concentrations of pioglitazone may increase due to inhibition of CYP2C8 and CYP3A4 but concentrations may decrease due to induction of CYP2C9. As the clinical relevance of this interaction is unknown, monitoring of blood glucose levels may be required.",(See Summary)
304,Idelalisib,Pipotiazine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. The metabolism of pipotiazine has not been well described but may involve CYP2D6. Idelalisib does not inhibit or induce CYP2D6.,(See Summary)
305,Idelalisib,Piroxicam,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Piroxicam is primarily metabolised by CYP2C9. Idelalisib does not inhibit or induce CYP2C9. ,(See Summary)
306,Idelalisib,Pitavastatin,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Pitavastatin is metabolised by UGTs 1A3 and 2B7 with minimal metabolism by CYPs 2C9 and 2C8. Idelalisib is an inhibitor of CYP2C8 in vitro and also an inducer of CYP2C9 and UGT in vitro but the in vivo effects have yet to be determined. As the clinical relevance of this interaction is unknown, monitoring may be required.",(See Summary)
307,Idelalisib,Posaconazole,"
Potential Interaction
","
Very Low
","Coadministration has not been studied and should be avoided. Posaconazole undergoes glucuronidation with only a small portion of CYP-mediated metabolism. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may increase concentrations of posaconazole. Therefore, coadministration should be avoided. If coadministration is clinically necessary, close monitoring for posaconazole toxicity is recommended. Furthermore, posaconazole is an inhibitor of CYP3A4 and may increase concentrations of idelalisib. Since the therapeutic index of idelalisib is relatively large, no priori dose adjustment is necessary but close monitoring for toxicity is recommended. ",(See Summary)
308,Idelalisib,Potassium,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on limited data available an interaction appears unlikely. Potassium is eliminated renally. ,(See Summary)
309,Idelalisib,Prasugrel,"
Potential Interaction
","
Very Low
","Coadministration has not been studied. Prasugrel is a prodrug and is converted to its active metabolite mainly by CYP3A4, CYP2B6 and to a lesser extent by CYP2C9 and CYP2C19. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may increase concentrations of prasugrel. Concentrations of the active metabolite may also be altered. Therefore coadministration should be avoided. If coadministration is clinically necessary, close monitoring of prasugrel efficacy is recommended. ",(See Summary)
310,Idelalisib,Pravastatin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pravastatin is minimally metabolised via CYP enzymes and is a substrate of OATP1B1. Idelalisib does not inhibit or induce OATP1B1.,(See Summary)
311,Idelalisib,Prazosin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Prazosin is extensively metabolised, primarily by demethylation and conjugation. Idelalisib does not interact with these metabolic pathways.",(See Summary)
312,Idelalisib,Prednisolone,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied and should be avoided. Prednisolone undergoes hepatic metabolism via CYP3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of prednisolone. Therefore, coadministration should be avoided. If coadministration is clinically necessary, close monitoring for prednisolone toxicity is recommended.",(See Summary)
313,Idelalisib,Prednisone,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied and should be avoided. Prednisone is converted to the active metabolite prednisolone by 11-B-hydroxydehydrogenase. Prednisolone is then metabolised by CYP3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of prednisolone. Therefore, coadministration should be avoided. If coadministration is clinically necessary, close monitoring for prednisolone toxicity is recommended.",(See Summary)
314,Idelalisib,Pregabalin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pregabalin is cleared mainly by glomerular filtration. Idelalisib does not interfere with this elimination pathway. ,(See Summary)
315,Idelalisib,Prochlorperazine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Prochlorperazine is metabolised by CYP2D6 and CYP2C19. Idelalisib does not inhibit or induce CYP2D6 or CYP2C19. ,(See Summary)
316,Idelalisib,Promethazine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Promethazine is metabolised by CYP2D6. Idelalisib does not inhibit or induce CYP2D6. ,(See Summary)
317,Idelalisib,Propafenone,"
Potential Interaction
","
Very Low
","Coadministration has not been studied. Propafenone is metabolised mainly by CYP2D6 and to a lesser extent by CYP1A2 and CYP3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may increase concentrations of propafenone. As the clinical relevance of this interaction is unknown, close monitoring for propafenone toxicity is recommended.",(See Summary)
318,Idelalisib,Propranolol,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Propranolol is metabolised by 3 routes (aromatic hydroxylation by CYP2D6, N-dealkylation followed by side chain hydroxylation via CYPs 1A2, 2C19, 2D6, and direct glucuronidation). Idelalisib does not inhibit or induce CYPs 2D6, 1A2, 2C19 or UGTs. ",(See Summary)
319,Idelalisib,Prucalopride,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Prucalopride is minimally metabolised and mainly renally eliminated, partly by active secretion by renal transporters. Prucalopride is a substrate of P-gp, but no clinically relevant interactions were observed when prucalopride was coadministered with inhibitors of renal P-gp, OAT and OCT transporters.",(See Summary)
320,Idelalisib,Pyrazinamide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pyrazinamide is mainly metabolised by xanthine oxidase. Idelalisib does not interact with this metabolic pathway. ,(See Summary)
321,Idelalisib,Pyridoxine (Vitamin B6),"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. ,(See Summary)
322,Idelalisib,Quetiapine,"
Do Not Coadminister
","
Low
","Coadministration has not been studied and should be avoided. Quetiapine is primarily metabolised by CYP3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of quetiapine. Therefore, coadministration should be avoided. Alternative antipsychotics, such as olanzapine, may be considered. ",(See Summary)
323,Idelalisib,Quinapril,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Quinapril is de-esterified to the active metabolite quinaprilat which is eliminated primarily by renal excretion via OAT3. Idelalisib does not interact this renal transporter. ,(See Summary)
324,Idelalisib,Quinidine,"
Do Not Coadminister
","
Low
","Coadministration has not been studied and is not recommended. Quinidine is metabolised by CYP3A4 and is an inhibitor of CYP2D6. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of quinidine. Therefore, coadministration should be avoided. If possible, selection of an alternate concomitant medicinal product, with no or minimal metabolism via CYP3A4 should be considered.",(See Summary)
325,Idelalisib,Rabeprazole,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Rabeprazole is mainly metabolised via non-enzymatic reduction and to a lesser extent by CYP2C19 and CYP3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and idelalisib is an inducer of CYP2C19 in vitro. Concentrations of rabeprazole may increase due to inhibition of CYP3A4 but concentrations may decrease due to induction of CYP2C19. Although rabeprazole has a wide therapeutic index, the clinical relevance of this interaction is unknown and monitoring for toxicity may be required. The solubility of idelalisib decreases with increasing pH of the stomach. However, in patients with chronic lymphoid leukaemia (CLL) and indolent non-Hodgkin lymphoma (iNHL), coadministration of idelalisib and acid-reducing agents did not demonstrate any clinically relevant effects. For patients with iNHL, idelalisib AUC and Cmax increased by 4% and 6%, respectively, whereas for patients with CLL, idelalisib AUC and Cmax decreased by 11% and 5%, respectively. Therefore, no clinically relevant interactions are expected. ",(See Summary)
326,Idelalisib,Ramipril,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied and should be avoided. Ramipril is hydrolysed to the active metabolite ramiprilat probably via CYP3A4, and is metabolised to the diketopiperazine ester, diketopiperazine acid and the glucuronides of ramipril and ramiprilat. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may decrease biotransformation to active substance. The clinical relevance of this interaction is unknown and coadministration should be avoided. If coadministration is clinically necessary, close monitoring of blood pressure may be required.",(See Summary)
327,Idelalisib,Ranitidine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ranitidine is excreted via OAT1/OAT3. Idelalisib does not interact with this pathway. However, the solubility of idelalisib decreases with increasing pH of the stomach, but in patients with chronic lymphoid leukaemia (CLL) and indolent non-Hodgkin lymphoma (iNHL), coadministration of idelalisib and acid-reducing agents did not demonstrate any clinically relevant effects. For patients with iNHL, idelalisib AUC and Cmax increased by 4% and 6%, respectively, whereas for patients with CLL, idelalisib AUC and Cmax decreased by 11% and 5%, respectively. Therefore, no clinically relevant interactions are expected.",(See Summary)
328,Idelalisib,Ranolazine,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied but should be avoided. Ranolazine is primarily metabolised by CYP3A4 and to a lesser extent by CYP2D6. Ranolazine is also a substrate of P-gp. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of ranolazine. Therefore, coadministration should be avoided. If coadministration is clinically necessary, close monitoring of blood pressure or dose titration is recommended. Idelalisib is also an inhibitor of P-gp in vitro. However, a clinically relevant interaction due to P-gp inhibition is unlikely. Furthermore, ranolazine is a weak inhibitor of P-gp, CYP3A4 and CYP2D6. Concentrations of idelalisib may increase due to CYP3A4 inhibition. Since the therapeutic index of idelalisib is relatively large, no a priori dose adjustment is necessary but close monitoring for toxicity is recommended.",(See Summary)
329,Idelalisib,Reboxetine,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied and should be avoided. In vitro data indicate reboxetine to be a weak inhibitor of CYP3A4 but in vivo data showed no inhibitory effect on CYP3A4. However, reboxetine is metabolised by CYP3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of reboxetine. Therefore, coadministration should be avoided. If coadministration is clinically necessary, close monitoring or dose titration is recommended. ",(See Summary)
330,Idelalisib,Repaglinide,"
Potential Interaction
","
Very Low
","Coadministration has not been studied. Repaglinide is metabolised by CYP2C8 and CYP3A4 with clinical data indicating it is also a substrate of the hepatic transporter OATP1B1. Idelalisib is an inhibitor of CYP2C8 and the primary metabolite of idelalisib (GS-563117) is also a strong inhibitor of CYP3A4. Therefore, concentrations of repaglinide may significantly increase and close monitoring of blood glucose levels may be required.",(See Summary)
331,Idelalisib,Retinol (Vitamin A),"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Vitamin A esters are hydrolysed by pancreatic enzymes to retinol, which is then absorbed and re-esterified. Some retinol is stored in the liver but retinol not stored in the liver undergoes glucuronide conjugation and subsequent oxidation to retinal and retinoic acid. Idelalisib does not interact with these metabolic pathways. ",(See Summary)
332,Idelalisib,Riboflavin (Vitamin B2),"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.,(See Summary)
333,Idelalisib,Rifabutin,"
Do Not Coadminister
","
Low
","Coadministration has not been studied and should be avoided. Rifabutin is metabolised by CYP3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of rifabutin. Therefore, coadministration should be avoided. If coadministration is clinically necessary, close monitoring for rifabutin associated adverse events including neutropenia and uveitis is recommended. Furthermore, rifabutin is an inducer of CYP3A4 and may significantly decrease concentrations of idelalisib. Coadministration should be avoided as a decrease in idelalisib exposure can lead to decreased efficacy. Selection of an alternative concomitant medication with no or minimal enzyme or transporter induction potential is recommended. Increasing the dose of idelalisib when coadministering with moderate or strong CYP3A inducers has not been studied and thus no formal dose advice can be given.  ",(See Summary)
334,Idelalisib,Rifampicin,"
Do Not Coadminister
","
Moderate
","Coadministration should be avoided. Rifampicin is metabolised via deacetylation. Idelalisib does not interfere with this metabolic pathway. However, rifampicin is an inducer of CYP3A4 and may significantly decrease concentrations of idelalisib. In healthy volunteers (n=12), rifampicin (600 mg once daily for 8 days) and idelalisib (single dose of 150 mg) decreased idelalisib AUC and Cmax by 75% and 58%, respectively. The AUC and Cmax of GS-563117, the active metabolite of idelalisib, decreased by 89% and 68%, respectively. Therefore, coadministration should be avoided as a decrease in idelalisib exposure can lead to decreased efficacy. Selection of an alternative concomitant medication with no or minimal enzyme or transporter induction potential is recommended. Increasing the dose of idelalisib when coadministering with moderate or strong CYP3A inducers has not been studied and thus no formal dose advice can be given. ",(See Summary)
335,Idelalisib,Rifapentine,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied and should be avoided. Rifapentine is metabolised via deacetylation. Idelalisib does not interfere with this metabolic pathway. However, rifapentine is an inducer of CYP3A4 and may significantly decrease concentrations of idelalisib. Therefore, coadministration should be avoided as a decrease in idelalisib exposure can lead to decreased efficacy. Selection of an alternative concomitant medication with no or minimal enzyme or transporter induction potential is recommended. Increasing the dose of idelalisib when co-administering with moderate or strong CYP3A inducers has not been studied and thus no formal dose advice can be given. ",(See Summary)
336,Idelalisib,Rifaximin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Rifaximin is mainly excreted in the faeces, almost entirely as unchanged drug. Idelalisib does not interact with this elimination pathway. ",(See Summary)
337,Idelalisib,Risperidone,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Risperidone is metabolised by CYP2D6 and to a lesser extent by CYP3A4. Risperidone is also a substrate of P-gp. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and idelalisib is an inhibitor of P-gp in vitro. Although CYP3A4 mediated metabolism is only a minor pathway, the clinical relevance of this interaction is unknown and monitoring may be required. ",(See Summary)
338,Idelalisib,Rivaroxaban,"
Potential Interaction
","
Very Low
","Coadministration has not been studied. Rivaroxaban is partly metabolised in the liver (by CYP3A4, CYP2J2 and hydrolytic enzymes) and partly eliminated unchanged in urine (by P-gp and BCRP). The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of rivaroxaban. Close monitoring of anti-Xa levels is recommended if coadministered.",(See Summary)
339,Idelalisib,Rosiglitazone,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Rosiglitazone is metabolised mainly by CYP2C8 and to a lesser extent by CYP2C9 and CYP3A4. Idelalisib is an inhibitor of CYP2C8 in vitro and the primary metabolite of idelalisib (GS-563117) is also a strong inhibitor of CYP3A4. Therefore, concentrations of rosiglitazone may increase due to inhibition of CYP2C8 and CYP3A4. As the clinical relevance of this interaction is unknown, monitoring may be required. ",(See Summary)
340,Idelalisib,Rosuvastatin,"
No Interaction Expected
","
Moderate
","Rosuvastatin is largely excreted unchanged via the faeces via OATP1B1/3. Idelalisib is an inhibitor of OATP1B1/3 in vitro. However, no clinically relevant interaction was observed in healthy volunteers (n=12). Coadministration of idelalisib (150 mg twice daily for 10 days) and rosuvastatin (single dose of 10 mg) increased rosuvastatin AUC and Cmax by 2% and 15%, respectively. ",(See Summary)
341,Idelalisib,Salbutamol,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Salbutamol is metabolised to the inactive salbutamol-4’-O-sulphate. Idelalisib does not interact with this metabolic pathway.,(See Summary)
342,Idelalisib,Salmeterol,"
No Interaction Expected
","
Low
","Coadministration has not been studied and should be avoided. Salmeterol is metabolised by CYP3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of salmeterol. Although the systemic absorption of salmeterol after bronchial administration is low, increased systemic exposure to salmeterol may occur. Therefore, coadministration should be avoided. Coadministration may also result in increased risk of cardiovascular adverse events associated with salmeterol (QT prolongation, palpitations, sinus tachycardia).",(See Summary)
343,Idelalisib,Saxagliptin,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied and should be avoided. Saxagliptin is mainly metabolised by CYP3A4 and is a substrate of P-gp. Idelalisib is an inhibitor of P-gp in vitro and the primary metabolite of idelalisib (GS-563117) is also strong inhibitor of CYP3A4. Therefore, concentrations of saxagliptin may significantly increase. Coadministration should be avoided. If coadministration of is clinically necessary, close monitoring of blood glucose levels or dose titration is recommended. ",(See Summary)
344,Idelalisib,Senna,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Senna glycosides are hydrolysed by colonic bacteria in the intestinal tract and the active anthraquinones liberated into the colon. Excretion occurs in the urine and the faeces and also in other secretions. No clinically significant drug interactions are known. ,(See Summary)
345,Idelalisib,Sertindole,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied and should be avoided. Sertindole is metabolised by CYP2D6 and CYP3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of sertindole. Therefore, coadministration should be avoided. If coadministration is clinically necessary, close monitoring or dose titration is recommended. ",(See Summary)
346,Idelalisib,Sertraline,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sertraline is mainly metabolised by CYP2B6 and to a lesser extent by CYPs 2C9, 2C19, 2D6 and 3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may increase concentrations of sertraline. However, since CYP3A4-mediated metabolism is only a minor pathway, a clinically relevant interaction is unlikely.",(See Summary)
347,Idelalisib,Sildenafil (Pulmonary Arterial Hypertension),"
Do Not Coadminister
","
Low
","Coadministration has not been studied and should be avoided. Sildenafil is metabolised mainly by CYP3A4 and to a lesser extent by CYP2C9. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and idelalisib is an inducer of CYP2C9 in vitro. Concentrations of sildenafil may significantly increase due to strong inhibition of CYP3A4 but concentrations may decrease due to induction of CYP2C9. Therefore, coadministration should be avoided. If possible, selection of an alternate concomitant medicinal product, with no or minimal metabolism via CYP3A4 should be considered.",(See Summary)
348,Idelalisib,Simvastatin,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied and should be avoided. Simvastatin is metabolised by CYP3A4 and the metabolite is a substrate of OATP1B1. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of simvastatin. Therefore, coadministration should be avoided. Replacement of lovastatin with pravastatin or rosuvastatin should be considered.",(See Summary)
349,Idelalisib,Sirolimus,"
Do Not Coadminister
","
Low
","Coadministration has not been studied and should be avoided. Sirolimus is metabolised by CYP3A4 and is substrate of P-gp. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of sirolimus. Therefore, coadministration should be avoided. If coadministration is clinically necessary, the dose of sirolimus should be decreased dependent on the indication and protocol involved, and monitoring of sirolimus plasma concentrations is recommended. Due to the risk of additive haematological toxicity, haematological parameters should also be monitored if coadministered.",(See Summary)
350,Idelalisib,Sitagliptin,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Sitagliptin is primarily eliminated in urine as unchanged drug (via active secretion by OAT3, OATP4C1, P-gp) with metabolism by CYP3A4 representing a minor elimination pathway. Idelalisib is an inhibitor of P-gp in vitro and the primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4. Therefore, concentrations of sitagliptin may increase. Although CYP3A4 mediated metabolism is a minor pathway, the clinical relevance of this is interaction is unknown and monitoring may be required.",(See Summary)
351,Idelalisib,Sodium nitroprusside,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sodium nitroprusside is rapidly metabolised, likely by interaction with sulfhydryl groups in the erythrocytes and tissues. Cyanogen (cyanide radical) is produced which is converted to thiocyanate in the liver by the enzyme thiosulfate sulfurtransferase. There is little potential for sodium nitroprusside to affect the disposition of idelalisib, or to be affected if coadministered with idelalisib. ",(See Summary)
352,Idelalisib,Sotalol,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sotalol is excreted unchanged via renal elimination. Idelalisib does not interfere with this elimination pathway. ,(See Summary)
353,Idelalisib,Spectinomycin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Spectinomycin is predominantly eliminated unchanged in the kidneys via glomerular filtration. Idelalisib does not interact with this elimination pathway. ,(See Summary)
354,Idelalisib,Spironolactone,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Spironolactone is partly metabolised by the flavin containing monooxygenases. Idelalisib does not interfere with this metabolic pathway. ,(See Summary)
355,Idelalisib,Stanozolol,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied and should be avoided. Stanozolol undergoes hepatic metabolism. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and idelalisib is an inhibitor of CYP2C8 in vitro. Concentrations of stanozolol may significantly increase due to inhibition of CYP3A4 and CYP2C8. Therefore, coadministration should be avoided. If coadministration is clinically necessary, close monitoring for stanozolol toxicity is recommended.",(See Summary)
356,Idelalisib,St John's Wort,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied and should be avoided. St John’s Wort may cause significant and unpredictable decreases in the plasma concentrations of idelalisib due to induction of CYP3A4 and P-gp. Therefore, coadministration should be avoided as a decrease in idelalisib exposure can lead to decreased efficacy. Selection of an alternative concomitant medication with no or minimal enzyme or transporter induction potential is recommended. Increasing the dose of idelalisib when coadministering with moderate or strong CYP3A/P-gp inducers has not been studied and thus no formal dose advice can be given.",(See Summary)
357,Idelalisib,Streptokinase,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Like other proteins, streptokinase is metabolised proteolytically in the liver and eliminated via the kidneys. Streptokinase is unlikely to affect the disposition of idelalisib, or to be affected if coadministered with idelalisib.",(See Summary)
358,Idelalisib,Streptomycin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Streptomycin is eliminated by glomerular filtration. Idelalisib does not interfere with this elimination pathway.,(See Summary)
359,Idelalisib,Sulfadiazine,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. In vitro studies suggest a role of CYP2C9 in sulfadiazine metabolism. Idelalisib is an inducer of CYP2C9 in vitro but the in vivo effect has yet to be determined. As the clinical relevance of this interaction is unknown, monitoring may be required. ",(See Summary)
360,Idelalisib,Sulpiride,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sulpiride is mainly excreted in the urine and faeces as unchanged drug. Idelalisib does not interfere with this elimination pathway.,(See Summary)
361,Idelalisib,Tacrolimus,"
Do Not Coadminister
","
Low
","Coadministration has not been studied and should be avoided. Tacrolimus is an inhibitor of CYP3A4 in vitro but produced modest inhibition of CYP3A4 in the range of clinical concentrations. Tacrolimus could potentially increase idelalisib concentrations although to a modest extent. Since the therapeutic index of idelalisib is relatively large, no a priori dose adjustment is necessary. However, tacrolimus is metabolised mainly by CYP3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of tacrolimus. Therefore, coadministration should be avoided. If coadministration is clinically necessary, the dose of tacrolimus should be decreased dependent on the indication and protocol involved, and monitoring of tacrolimus plasma concentrations is recommended. Due to the risk of additive haematological toxicity, haematological parameters should be monitored if coadministered.",(See Summary)
362,Idelalisib,Tadalafil (Pulmonary Arterial Hypertension),"
Do Not Coadminister
","
Low
","Coadministration has not been studied and should be avoided. Tadalafil is metabolised by CYP3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of tadalafil. Coadministration should be approached with caution. If coadministration is clinically necessary, close monitoring and dose titration is recommended. ",(See Summary)
363,Idelalisib,Tamsulosin,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied and should be avoided. Tamsulosin is metabolised mainly by CYP3A4 and to a lesser extent by CYP2D6. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of tamsulosin. Therefore, coadministration should be avoided. If coadministration is clinically necessary, close monitoring or dose titration is recommended. ",(See Summary)
364,Idelalisib,Tazobactam,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tazobactam is excreted as unchanged drug (approximately 80%) and inactive metabolite (approximately 20%) in the urine. Idelalisib does not interact with this elimination pathway.,(See Summary)
365,Idelalisib,Telithromycin,"
Do Not Coadminister
","
Low
","Coadministration has not been studied and should be avoided. Telithromycin is an inhibitor of CYP3A4 and may increase concentrations of idelalisib. Since the therapeutic index of idelalisib is relatively large, no a priori dose adjustment is necessary. However, close monitoring for toxicity is recommended. Furthermore, telithromycin is metabolised by CYP3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of telithromycin. Therefore, coadministration should be avoided. If coadministration is clinically necessary, close monitoring for telithromycin associated adverse events is recommended. ",(See Summary)
366,Idelalisib,Telmisartan,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Telmisartan is mainly glucuronidated by UGT1A3. Idelalisib not inhibit or induce UGT1A3. ,(See Summary)
367,Idelalisib,Temazepam,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Temazepam is mainly glucuronidated. Idelalisib does not interact with this metabolic pathway. ,(See Summary)
368,Idelalisib,Terbinafine,"
Potential Interaction
","
Very Low
","Coadministration has not been studied. Terbinafine is metabolised by CYPs 1A2, 2C9, 3A4 and to a lesser extent by CYPs 2C8 and 2C19. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and idelalisib is an inhibitor of CYP2C8 in vitro. Concentrations of terbinafine may significantly increase due to inhibition of CYP3A4 and CYP2C8. Multiple pathways are involved in terbinafine metabolism, but the clinical relevance of this is interaction is unknown and close monitoring may be required. ",(See Summary)
369,Idelalisib,Testosterone,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied and should be avoided. Testosterone is metabolised by CYP3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of testosterone. Therefore, coadministration should be avoided. If coadministration is clinically necessary, close monitoring for testosterone toxicity is recommended.",(See Summary)
370,Idelalisib,Tetracycline,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tetracycline is eliminated unchanged primarily by glomerular filtration. Idelalisib does not interfere with this elimination pathway.,(See Summary)
371,Idelalisib,Theophylline,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Theophylline is mainly metabolised by CYP1A2. Idelalisib does not inhibit or induce CYP1A2.,(See Summary)
372,Idelalisib,Thiamine (Vitamin B1),"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. ,(See Summary)
373,Idelalisib,Thioridazine,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Thioridazine is metabolised by CYP2D6 and to a lesser extent by CYP3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may increase concentrations of thioridazine. Although CYP3A4 mediated metabolism is only a minor pathway, the clinical relevance of this interaction is unknown and monitoring may be required.",(See Summary)
374,Idelalisib,Tiapride,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as tiapride is excreted largely unchanged in urine. Idelalisib does not interfere with this elimination pathway.,(See Summary)
375,Idelalisib,Ticagrelor,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied and should be avoided. Ticagrelor is a weak inhibitor of CYP3A4 and may increase concentrations of idelalisib, although this this unlikely to be clinically relevant. However, ticagrelor undergoes extensive CYP3A4 metabolism. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of ticagrelor. Therefore, coadministration should be avoided. If coadministration of is clinically necessary, close monitoring or dose titration is recommended. ",(See Summary)
376,Idelalisib,Timolol,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Timolol is predominantly metabolised in the liver by CYP2D6. Idelalisib does not inhibit or induce CYP2D6.,(See Summary)
377,Idelalisib,Tinzaparin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tinzaparin is renally excreted as unchanged or almost unchanged drug. Idelalisib does not interact with this elimination pathway.,(See Summary)
378,Idelalisib,Tolbutamide,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tolbutamide is mainly metabolised by CYP2C9 and to a lesser extent by CYPs 2C8 and 2C19. Idelalisib is an inhibitor of CYP2C8 in vitro and may slightly increase concentrations of tolbutamide. Since CYP2C8-mediated metabolism is only a minor pathway, a clinically relevant interaction is unlikely. ",(See Summary)
379,Idelalisib,Tolterodine,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Tolterodine is primarily metabolised by CYP2D6 with CYP3A4 playing a minor role. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may increase concentrations of tolterodine. Although CYP3A4 mediated metabolism is only a minor pathway, the clinical relevance of this interaction is unknown and monitoring for toxicity may be required. ",(See Summary)
380,Idelalisib,Torasemide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Torasemide is metabolised mainly by CYP2C9. Idelalisib does not inhibit or induce CYP2C9. ,(See Summary)
381,Idelalisib,Tramadol,"
Potential Interaction
","
Very Low
","Coadministration has not been studied. Tramadol is metabolised by CYPs 3A4, 2B6, and 2D6. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may increase concentrations of tramadol. Although CYP3A4 mediated metabolism is one of many metabolic pathways, close monitoring for tramadol toxicity is recommended.",(See Summary)
382,Idelalisib,Trandolapril,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied and should be avoided. Trandolapril is hydrolysed to the active metabolite, trandolaprilat, probably via CYP3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of trandolapril. Therefore, coadministration should be avoided. If coadministration is clinically necessary, close monitoring of blood pressure or dose titration is recommended. ",(See Summary)
383,Idelalisib,Tranexamic acid,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as tranexamic acid is mainly cleared by glomerular filtration. Idelalisib does not interfere with this elimination pathway.,(See Summary)
384,Idelalisib,Tranylcypromine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tranylcypromine is hydroxylated and acetylated. Idelalisib does not interact with these metabolic pathways. ,(See Summary)
385,Idelalisib,Trazodone,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied and should be avoided. Trazodone is primarily metabolised by CYP3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of trazodone. Therefore, coadministration should be avoided. If coadministration is clinically necessary, careful dose titration and monitoring for trazodone response is recommended.",(See Summary)
386,Idelalisib,Triamcinolone,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied and should be avoided. Triamcinolone is metabolised by CYP3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of triamcinolone. Therefore, coadministration should be avoided. If coadministration is clinically necessary, close monitoring for triamcinolone toxicity is recommended.",(See Summary)
387,Idelalisib,Triazolam,"
Do Not Coadminister
","
Low
","Coadministration has not been studied and should be avoided. Triazolam is metabolised by CYP3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of triazolam. Therefore, coadministration should be avoided. Replacement of triazolam with an alternative sedative agent, such as temazepam, nitrazepam or lorazepam should be considered.",(See Summary)
388,Idelalisib,Trimethoprim/Sulfamethoxazole,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Trimethoprim is primarily eliminated in the kidneys via glomerular filtration and tubular secretion. In vitro data suggest that trimethoprim inhibits the renal transporters OCT2 and MATE1 but this is unlikely to affect idelalisib concentrations. Sulfamethoxazole is metabolised via CYP2C9. Idelalisib is an inducer of CYP2C9 in vitro but the in vivo effect has yet to be determined. As the clinical relevance of this interaction is unknown, monitoring may be required. ",(See Summary)
389,Idelalisib,Trimipramine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Trimipramine is metabolised mainly by CYP2D6. Idelalisib does not inhibit or induce CYP2D6. ,(See Summary)
390,Idelalisib,Tropisetron,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tropisetron is metabolised mainly by CYP2D6 and is a substrate of P-gp. Idelalisib is an inhibitor of P-gp in vitro but a clinically relevant interaction with substrates of systemic P-gp is unlikely. ,(See Summary)
391,Idelalisib,Ulipristal,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Ulipristal is mainly metabolised by CYP3A4 and to a lesser extent by CYP1A2 and CYP2D6. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may increase concentrations of ulipristal. Although ulipristal has a wide therapeutic window, the clinical relevance of this interaction is unknown and monitoring may be required. The SPC for idelalisib states that women using hormonal contraceptives should add a barrier method as a second form of contraception while taking idelalisib and for 1 month after stopping treatment, as it is currently unknown whether idelalisib may reduce the effectiveness.",(See Summary)
392,Idelalisib,Valproic acid (Valproate),"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Valproic acid is primarily metabolised by glucuronidation (50%) and mitochondrial beta-oxidation (30-40%). To a lesser extent (10%) valproic acid is metabolised by CYP2C9 and CYP2C19. Valproic acid is also an inhibitor of CYP2C9. Idelalisib does not interact with this pathway.,(See Summary)
393,Idelalisib,Valsartan,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Valsartan is eliminated unchanged mostly through biliary excretion. Idelalisib does not interact with this elimination pathway.,(See Summary)
394,Idelalisib,Vancomycin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Vancomycin is excreted unchanged via glomerular filtration. Idelalisib does not interfere with this elimination pathway.,(See Summary)
395,Idelalisib,Venlafaxine,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Venlafaxine is mainly metabolised by CYP2D6 and to a lesser extent by CYPs 3A4 and 2C19 and 2C9. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may increase concentrations of venlafaxine. Although CYP3A4 mediated metabolism is only a minor pathway, the clinical relevance of this interaction is unknown and monitoring of toxicity may be required.",(See Summary)
396,Idelalisib,Verapamil,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied and should be avoided. Verapamil is a moderate inhibitor of CYP3A4 and may increase concentrations of idelalisib. Since the therapeutic index of idelalisib is relatively large, no a priori dose adjustment is necessary but close monitoring for toxicity is recommended. Verapamil is metabolised mainly by CYP3A4 and to a lesser extent by CYPs 1A2, 2C8 and 2C9. Idelalisib is an inhibitor of CYP2C8 in vitro and the primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4. Furthermore, idelalisib is an inducer of CYP2C9 in vitro but the in vivo effect has yet to be determined. Concentrations of verapamil may significantly increase due to inhibition of CYP3A4 and CYP2C8 by idelalisib but concentrations may decrease due to induction of CYP2C9. Therefore, coadministration should be avoided. If coadministration is clinically necessary, close monitoring of therapeutic effect (blood pressure) and adverse reactions is recommended. ",(See Summary)
397,Idelalisib,Vildagliptin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Vildagliptin is inactivated via non-CYP mediated hydrolysis. Additionally, vildagliptin is also a substrate of P-gp. Idelalisib is an inhibitor of P-gp in vitro. However, a clinically relevant interaction is unlikely with substrates of systemic P-gp.",(See Summary)
398,Idelalisib,Vitamin E,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. ,(See Summary)
399,Idelalisib,Voriconazole,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied and should be avoided. Voriconazole is an inhibitor of CYP3A4 and may increase concentrations of idelalisib. Since the therapeutic index of idelalisib is relatively large, no a priori dose adjustment is necessary but close monitoring for toxicity is recommended. Furthermore, voriconazole is metabolised by CYPs 2C9, 2C19 and 3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of voriconazole. Therefore, coadministration should be avoided. If coadministration is clinically necessary, close monitoring for voriconazole toxicity is recommended. ",(See Summary)
400,Idelalisib,Warfarin,"
Potential Interaction
","
Moderate
","Coadministration has not been studied and should be avoided. Warfarin is a mixture of enantiomers which are metabolised by different cytochromes. R-warfarin is primarily metabolised by CYP1A2 and CYP3A4. S-warfarin (more potent) is metabolised by CYP2C9. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of warfarin. Therefore, coadministration should be avoided. If coadministration is clinically necessary, close monitoring of the INR upon and following cessation of treatment with idelalisib is recommended. ",(See Summary)
401,Idelalisib,Xipamide,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Approximately 90% of xipamide is excreted in the urine, mainly as unchanged drug (~50%) and glucuronides (30%). ",(See Summary)
402,Idelalisib,Zaleplon,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Zaleplon is mainly metabolised by aldehyde oxidase and to a lesser extent by CYP3A4. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may increase concentrations of zaleplon. Although zaleplon is only partly metabolised by CYP3A4 and does not have a narrow therapeutic index, the clinical relevance of this is interaction is unknown and monitoring of toxicity may be required. ",(See Summary)
403,Idelalisib,Ziprasidone,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Approximately two thirds of ziprasidone metabolic clearance is by reduction, with less than one third by CYP enzymes (mainly CYP3A4). The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4. Although CYP3A4 mediated metabolism is only a minor pathway, the clinical relevance of this interaction is unknown and monitoring may be required.",(See Summary)
404,Idelalisib,Zoledronic acid,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as zoledronic acid is not metabolised and is cleared as unchanged drug via urine.,(See Summary)
405,Idelalisib,Zolpidem,"
Do Not Coadminister
","
Low
","Coadministration has not been studied and should be avoided. Zolpidem is metabolised mainly by CYP3A4 and to a lesser extent by CYPs 2C9, 1A2, 2D6 and 2C19. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of zolpidem. Therefore, coadministration should be avoided. If coadministration is clinically necessary, close monitoring for zolpidem toxicity and a dose reduction of zolpidem should be considered.",(See Summary)
406,Idelalisib,Zopiclone,"
Potential Interaction
","
Very Low
","Coadministration has not been studied. Zopiclone is metabolised mainly by CYP3A4 and to a lesser extent by CYP2C8. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of zopiclone. As the clinical relevance of this is interaction is unknown, monitoring for toxicity and a dose reduction may be required. ",(See Summary)
407,Idelalisib,Zotepine,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied and should be avoided. Zotepine is mainly metabolised by CYP3A4 and to a lesser extent by CYP1A2 and CYP2D6. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of zotepine. Therefore, coadministration should be avoided. If coadministration is clinically necessary, close monitoring or dose titration is recommended.",(See Summary)
408,Idelalisib,Zuclopenthixol,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied and should be avoided. Zuclopenthixol is metabolised by sulphoxidation, N-dealkylation (via CYP2D6 and CYP3A4) and glucuronidation. The primary metabolite of idelalisib (GS-563117) is a strong inhibitor of CYP3A4 and may significantly increase concentrations of zuclopenthixol. Therefore, coadministration should be avoided. If coadministration is clinically necessary, close monitoring or dose titration is recommended. ",(See Summary)
